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Abstract 
Radiotherapy is commonly used in the treatment of head and neck cancer. For early 
stage tumours, conventional radiotherapy techniques have a high cure rate and low 
levels of long-term complications. Patients with more advanced cancers have much 
lower cure rates and high levels of treatment-related complications. Intensity-
modulated radiotherapy (IMRT) is a new form of focussed radiation therapy. It has 
been used to reduce the radiation dose to normal tissue structures and increase the 
dose delivered to tumour bearing tissues. This potentially allows reduced side effects 
and increased tumour control compared to conventional radiotherapy. The rationale 
of this thesis was to test whether these twin goals could be achieved in head and neck 
cancer patients. 
The first part of the thesis describes improvements in patient immobilisation, 
optimisation of techniques for neck irradiation, and evaluation of the technique in a 
busy radiotherapy department. It includes pre-clinical evaluation of IMRT for 
different tumour sites, the development of quality assurance programs and the 
conduct of a national randomised controlled trial of parotid-sparing IMRT. This trial 
concluded that IMRT significantly reduced patient-reported xerostomia, allowed 
recovery of saliva production and improved quality of life. The second part of the 
thesis describes pre-clinical evaluation of techniques to escalate radiation dose in 
patients with larynx and hypopharynx tumours. A phase I/II clinical trial showed that 
higher doses of radiation can be delivered at the expense of an increase in acute 
radiation toxicity but without a measurable increase in late radiation side effects. In 
the larynx and hypopharynx groups, a possible increase in local control was observed. 
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This thesis describes the process of evaluation of a new radiotherapy technology and 
could be used as a template for testing other new technologies in the future. 
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Chapter 1  
A decade of research in head and neck cancer 
radiotherapy 
Chapter 1 
12 
 
 
1.1 Setting the scene 
This PhD by prior publication presents a thesis of 10 research papers describing 
research work carried out between 2001 and 2011.  The papers presented here are a 
development of earlier work undertaken during my clinical research fellowship at The 
Institute of Cancer Research (ICR) between 1998 and 2000 which was awarded MD 
(res) in 2001. My MD (res) supervisors were Steve Webb, Professor of Medical 
Physics, and David Dearnaley, Professor of Prostate Cancer Studies.  I worked in the 
department of medical physics on a new form of radiotherapy called intensity-
modulated radiotherapy (IMRT), a new technique aimed at focussing radiation in a 
more accurate way to treat cancer. This was a very interesting time working as the 
only doctor in a department of physicists and engineers to develop this treatment 
technique. I was able to demonstrate the potential advantages of IMRT to allow 
normal tissue sparing and escalation of radiation dose for more effective and safer 
treatment for a variety of tumours. In the MD (res) thesis I described new 
radiotherapy techniques for tumours of the thyroid (Nutting, Convery et al. 2001), 
parotid (Nutting, Rowbottom et al. 2001) (Rowbottom, Nutting et al. 2001), 
oesophagus (Nutting, Bedford et al. 2002) and prostate (Nutting, Convery et al. 
2000). In 2000 I travelled to Memorial Sloane Kettering Hospital in New York where 
I worked with Dr Michael Zelefsky who was the first person to treat prostate cancer 
with IMRT. Later I spent a few weeks at the University of Michigan in Ann Arbor 
with my now great friend Dr Avi Eisbruch who taught me what he had learnt about 
applying IMRT to patients with head and neck cancer. I was amazed to see his 
patients who appeared to recover full function of speech and swallow, following 
IMRT - something I had rarely seen with conventional radiotherapy during my 
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training. On my return to the UK, we treated the first patient with IMRT at the Royal 
Marsden Hospital (RMH) in September 2000. This was the first delivery of IMRT in 
the UK, and was to a man with prostate cancer. 
 
In 2001 I was appointed as Consultant in Clinical Oncology at the RMH and 
Honorary Senior Lecturer at the ICR. My main initial goal was to develop IMRT for 
the treatment of head and neck cancer patients as I had seen at the University of 
Michigan and to develop trials to see if IMRT was really of benefit for head and neck 
cancer patients compared to conventional radiotherapy. Radiotherapy is a complex 
treatment requiring close collaboration between clinical oncologists, medical 
physicists, and therapy radiographers. To develop, implement, and evaluate a new 
radiotherapy technique in clinical trials requires an even larger team comprising 
specialists in clinical trials (statisticians, trial managers, and data collectors), 
academic physicists, and other research staff. In the early years my work was 
achieved from a small close working team. Catherine Clarke, an excellent medical 
physicist who we recruited from University of California San Francisco (UCSF), 
provided medical physics leadership. Elizabeth Miles was appointed as a Research 
Radiographer and was responsible for developing departmental protocols for 
treatment of patients. As the project developed I began collaborations with the 
Clinical Trials and Statistics Unit (CTSU) at the ICR where Emma Hall and I built 
what is now an active head and neck trials group. For that reason the papers presented 
here have multiple authors and my contribution to the individual papers is detailed in 
Chapter 1 of this thesis.   
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When I started the IMRT research program at the RMH in 2001 I saw two major 
problems in head and neck cancer. First, for many tumour sites there were high levels 
of long-term treatment-related toxicity following radiotherapy (Mendes, Nutting et al. 
2002). Second, for patients with advanced stage disease, there were poor rates of local 
tumour control and survival (Royal College of Pathologists 2005 (2nd Edition)). It 
appeared to me that the most important toxicities were due to the irradiation of non 
target organs. For example, xerostomia was the most commonly reported late 
radiation side effect and it was predominantly due to the irradiation of the parotid 
glands which generate 80% of the saliva. It seemed logical that development of 
radiation techniques which reduced the dose to these organs was likely to lead to 
improvements in long-term side effects (Nutting, Dearnaley et al. 2000). For 
advanced tumours with poor local control rates, there was a need to increase the 
delivered dose to improve local control and survival (Harrington and Nutting 2002). 
This formed the rationale for the research work presented in this thesis.  
 
Head and neck cancer seemed an ideal site to test IMRT as the patient is easily 
immobilised with limited internal organ motion.  The close anatomical relationship 
between the tumour tissues and critical normal tissue structures is challenging for 
conventional radiotherapy but IMRT seemed to offer the potential to spare some 
normal tissue structures and deliver higher doses to tumours. For squamous cell 
carcinomas, the close relationship between delivered radiation dose and probability of 
tumour control made head and neck cancer a very attractive model for testing dose 
escalation strategies.  
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As with all new technologies there was a learning curve in the first few months and 
years of applying this technique. At The ICR/RMH a clinical implementation process 
was underway for IMRT for a number of tumour sites. This process started with the 
identification of appropriate tumour sites and the design of efficient delivery 
techniques. Initial clinical testing of IMRT techniques in Phase I/II studies was 
followed by Phase III randomised studies to confirm the clinical benefits of these new 
techniques. In tumour sites when the delivered dose of radiation was standard, then I 
proceeded directly to a Phase III study once the radiotherapy technique had been 
worked out. If the tumour site being studied involved delivering higher radiation 
dose, then I felt it was more appropriate to study the technique in Phase I/II trials to 
assess safety of dose escalation before moving on to Phase III trials. 
 
In this thesis I present a program of research in head and neck cancer IMRT designed 
to evaluate the ability of the technology to reduce the dose to a variety of organs at 
risk (OAR) and to test the potential of IMRT dose escalation to improve tumour 
control.  
 
1.2 The Papers Submitted as part of this thesis 
The full texts of the papers submitted for this PhD by prior publication are included at 
the end of the thesis.  
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1.3 The Story 
 
1.3.1 Head and neck cancer 
Head and neck cancers include cancers of the upper aerodigestive tract (including the 
oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx), the paranasal 
sinuses, and the salivary glands. Cancers at different sites have different clinical 
behaviours and variable histopathological types. Squamous cell carcinoma is by far 
the most common. The anatomical sites affected are important for functions such as 
speech, swallowing, taste, and smell, so the cancers and their treatments may have 
considerable functional sequelae with subsequent impairment of quality of life. 
Decisions about treatment are usually complex, and they must balance efficacy of 
treatment and likelihood of survival, with potential functional and quality of life 
outcomes. Patients and their carers need considerable support during and after 
treatment. 
 
1.3.2 Incidence and epidemiology 
Cancer of the mouth and oropharynx is the 10th most common cancer worldwide, but 
it is the seventh most common cause of cancer-induced mortality (Mehanna, Paleri et 
al. 2011). In 2002, the World Health Organization estimated that there were 600,000 
new cases of head and neck cancer and 300,000 deaths each year worldwide, with the 
most common sites being the oral cavity (389,000 cases a year), the larynx (160,000), 
and the pharynx (65,000) (Boyle and Levin 2008). The male to female ratio reported 
by large scale epidemiological studies and national cancer registries varies from 2:1 
to 15:1 depending on the site of disease. This is thought to be due to the higher 
exposure to carcinogens in alcohol and cigarette smoke in men than women.  The 
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incidence of cancers of the head and neck increases with age. In Europe, 98% and 
50% of patients diagnosed are over 40 and 60 years of age, respectively (Boyle and 
Levin 2008). 
 
1.3.2.1 Geographical factors 
A high incidence of head and neck cancer is seen in the Indian subcontinent, 
Australia, France, Brazil, and Southern Africa (World Health Organization and 
International Union Against Cancer 2005) . Nasopharyngeal cancer is largely 
restricted to southern China. The incidence of oral, laryngeal, and other smoking-
related cancers is declining in North America and Western Europe, primarily because 
of decreased exposure to carcinogens, especially tobacco (Boyle and Levin 2008). In 
contrast, because of the 40 year temporal gap between changes in population tobacco 
use and its epidemiological effects, the worst of the tobacco epidemic has yet to 
materialise in developing countries. WHO projections estimate worldwide mortality 
figures from mouth and oropharyngeal cancer in 2008 to be 371,000. This is 
projected to rise to 595,000 in 2030 because of a predicted rise in life expectancy in 
South East Asia. Modest rises are predicted in Africa, the Americas, and the Middle 
East, whereas mortality in Europe is expected to remain stable (Mathers and Loncar 
2006). This makes head and neck cancer a huge health burden worldwide for the 
foreseeable future. 
 
Several retrospective analyses of tumour samples collected from patients recruited in 
randomised trials, as well as retrospective patient series, have shown recent changes 
in epidemiology and pathogenesis of head and neck cancers related to the human 
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papillomavirus (HPV), especially for oropharyngeal carcinoma. A rapid rise in HPV-
related oropharyngeal cancers in particular has been shown in epidemiological studies 
from the developed world (Mehanna, Jones et al. 2010). For example, the United 
Kingdom has seen a doubling in the incidence of oropharyngeal cancer (from 
1/100,000 population to 2.3/100,000) in just over a decade (Mehanna, Paleri et al. 
2011). A recent retrospective study showed a progressive proportional increase in the 
detection of HPV in oropharyngeal squamous cell carcinomas in Stockholm over the 
past three decades: 23% in the 1970s, 29% in 1980s, 57% in 1990s, 68% between 
2000 and 2002, 77% between 2003 and 2005, and 93% between 2006 and 2007 
(Nasman, Attner et al. 2009).  
 
1.3.2.2 Risk factors for head and neck cancer 
The major risk factors are tobacco (smoking and smokeless products such as betel 
quid) and alcohol. They account for about 75% of cases, and their effects are 
multiplicative when combined (Conway, Hashibe et al. 2009). Smoking is more 
strongly associated with laryngeal cancer and alcohol consumption with cancers of 
the pharynx and oral cavity. Pooled analyses of 15 case-control studies showed that 
non-smokers who have three or more alcoholic drinks (beer or spirits) a day have 
double the risk of developing the disease compared with non-drinkers (odds ratio 
2.04, 95% confidence interval 1.29 to 3.21) (Purdue, Hashibe et al. 2009) (Hashibe, 
Brennan et al. 2007).  
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1.3.3 Diagnosis of head and neck cancer 
Patients with head and neck cancer present with a variety of symptoms, depending on 
the function of the site where the tumour originates. Laryngeal cancers commonly 
present with hoarseness, whereas pharyngeal cancers often present late with 
dysphagia or sore throat. Many often present with a painless neck node. Patients with 
head and neck cancer can present with non-specific symptoms or symptoms 
commonly associated with benign conditions, such as sore throat or ear pain.  
 
1.3.3.1 Investigation of head and neck cancer 
Examination of any lesion of the head or neck should include careful examination of 
the patient’s neck and mucosal surfaces (Paleri, Staines et al. 2010). Flexible 
nasolaryngoscopy allows detailed examination of the nasal cavities, postnasal space, 
base of the tongue, larynx, and hypopharynx.  
Examination under anaesthetic and biopsy allows assessment of the size, 
histopathological nature and extent of the primary tumour. FNA or core biopsy can 
provide cytological evidence of nodal metastasis (van den Brekel, Castelijns et al. 
1993). 
 
1.3.3.2 Imaging 
Computed tomography (CT) scanning from the skull base to the diaphragm is the first 
line investigation to assess nodal metastasis and identify the primary tumour site and 
tumour size. CT scanning has an important role in planning the extent of local 
therapies, such as surgery and radiotherapy (Newbold, Partridge et al. 2006).  
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Magnetic resonance imaging (MRI) is indicated for oral cavity and oropharyngeal 
tumours; in some cases it provides better information than CT, because of the absence 
of interference from dental amalgam and the better delineation of soft tissue 
extension. It can also be used for treatment planning (Ahmed, Schmidt et al. 2010). 
 
Ultrasound (US) -guided fine needle aspiration (FNA) of tumour contents performed 
by experienced practitioners is highly accurate and is used by some centres to 
diagnose nodal metastasis as part of disease staging (van den Brekel, Castelijns et al. 
1993). 
 
The new technique of fusion positron emission tomography-computerised 
tomography (PET-CT) has become one of the most important diagnostic tools for 
head and neck cancers. It combines normal CT scanning with functional imaging 
using 18F-fluorodeoxyglucose (18F-FDG), which is taken up preferentially by cells 
with high metabolic activity, especially cancer cells (Newbold, Partridge et al. 2008). 
This technique can therefore help identify occult primary tumours, which are 
relatively uncommon and not detected by examination and conventional imaging 
(Newbold, Partridge et al. 2008). The technique may also have a role in the 
assessment of persistent nodal disease after treatment and in the monitoring and 
follow-up of patients with head and neck cancer in the longer term, but sufficient 
evidence to support this is not yet available (Isles, McConkey et al. 2008). 
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1.3.4 Treatment of head and neck cancer 
Management is increasingly being delivered by specialists, whose main interest is 
cancers of the head and neck. Multidisciplinary care has now become the standard of 
care, often encouraged by national guidelines and protocols (National Institute for 
Health and Clinical Excellence 2004) (Scottish Intercollegiate Guidelines Network 
2006). The complexities of combined surgery and radiotherapy, as well as 
rehabilitation, means that a team of health professionals is needed to deliver high 
quality care to patients treated for head and neck cancer. An ideal team usually 
includes head and neck surgeons from different disciplines, clinical and medical 
oncologists, clinical nurse specialists, speech and language therapists, dieticians, 
psychologists, restorative dentists, prosthodontists, and social workers. Although we 
have no data to prove that multidisciplinary treatment has improved care, intuitively 
and anecdotally that seems to be the case.  
 
Radiotherapy and surgery are the two most common curative treatments for cancers 
of the head and neck. The choice of treatment modality depends on individual factors 
related to the site of the tumour and stage, but also patient preference. 
 
1.3.4.1 Early stage tumours 
Case series, often retrospective and from single centres, have shown that for early 
stage tumours in many head and neck subsites, surgical excision or radiotherapy have 
similar cure rates but a different side effect profile (Bhalavat, Fakih et al. 2003). 
Radiotherapy may offer better organ preservation, and for some cancers where 
function is important this is the treatment of choice. For example, radiotherapy allows 
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preservation of natural speech and swallowing in carcinomas of the tongue base. For 
some sites (such as the oral tongue), mainly retrospective single centre case series 
have shown that surgical excision alone may be curative, and that it is associated with 
a highly satisfactory functional outcome by retaining natural speech and swallow as 
assessed by a variety of validated techniques and patient surveys (Dwivedi, Chisholm 
et al. 2011) (Bhalavat, Fakih et al. 2003). 
 
1.3.4.2 Advanced tumours 
For advanced squamous cell carcinoma of the head and neck, single modality 
treatment (surgery or radiotherapy) is associated with poorer outcomes (Bhalavat, 
Fakih et al. 2003), and randomised studies have shown that combined use of surgery 
and postoperative radiotherapy, or combined chemotherapy and radiotherapy, offer 
the highest chance of achieving a cure (VA Laryngeal Cancer Study Group 1991; 
Bhalavat, Fakih et al. 2003) . 
 
1.3.4.3 Patients with HPV-related cancer 
Retrospective analyses of patients with oropharyngeal carcinoma show that HPV 
positive tumours seem to respond better to a variety of treatments, including 
chemoradiotherapy or surgery and radiotherapy than those who are HPV negative 
(Fakhry, Westra et al. 2008) (Ang 2010) (Licitra, Perrone et al. 2006). Because these 
patients are generally younger, they may survive for several decades with substantial 
side effects and functional impairment as a consequence of the treatment they receive, 
and this may have implications for carers, the health system, and social care (Harris, 
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Thorne et al. 2011). The anticipated loss of quality adjusted life years in this subgroup 
of head and neck cancer makes it even more important to minimize long-term 
toxicity. 
 
1.3.5 Role of radiation therapy in head and neck cancer 
Head and neck cancer is commonly treated with radiotherapy. High doses of 
radiation, typically 60-70 Gy, are required to eradicate tumours successfully. The 
close proximity of tumours to radiosensitive normal tissues means that, for many 
patients, successful cure is associated with sequelae of long-term radiation damage to 
these normal tissues. These include general tissue fibrosis and atrophy leading to 
stiffness of the tissues. Furthermore, several specific organ dysfunctions are observed. 
These include severe dryness of the mouth (xerostomia) due to damage to salivary 
glands leading to difficulties with speech, swallowing and poor oral hygiene. 
Swallowing difficulties are common due to damage to the muscles and nerves of the 
pharynx (Mendes, Nutting et al. 2004). 
 
1.3.5.1 Conventional radiotherapy 
Conventional radiotherapy techniques have for many years used simple parallel-
opposed fields to treat head and neck cancer. Typically treatment was planned using 
orthogonal plain radiographs using a simulator and field borders were based on 
standard anatomical bony landmarks. While these techniques provided adequate 
tumour coverage, there was little opportunity to spare adjacent normal tissues, leading 
to many of the side effects detailed above. 
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1.3.5.2 Three dimensional conformal radiotherapy  
Three dimensional conformal radiotherapy (3DCRT) became available for the 
treatment of head and neck cancer in the 1990s. This technique used 3-dimensional 
anatomical data in the form of a CT scan to identify more accurately the position and 
shape of the tumour target. Multi-leaf collimators (MLCs) allowed individual beam 
shaping which conformed the radiation dose more closely to the tumour and reduced 
the volume of normal tissue irradiated. While this had clinical benefits for some 
tumour types (e.g. prostate cancer see Table 1.1), in head and neck cancer there was 
little impact on late normal tissue radiation reactions because the key organs at risk 
were still within the high dose volume (Bhide and Nutting 2010). 
 
Site Author Benefits 
Prostate Dearnaley 1994 46% and 41% reduction of dose to rectum 
and bladder 
Paranasal sinus Adams 2001 Reduced optic nerve dose by 10%, parotid 
gland dose by 30%, potential to dose escalate 
Thorax Nutting 1999 Reduced lung irradiation, improved target 
homogeneity 
Oropharynx Eisbruch 1998 Reduced parotid gland irradiation 
Brain Khoo 1999 Reduced normal tissue irradiation by 40% 
 
Table 1.1 The benefits of 3-dimensional radiotherapy for a variety of tumour sites  
  
1.3.5.3 Intensity-modulated radiotherapy 
Intensity-modulated radiotherapy (IMRT) was developed in the late 1990s and 
represented progress in conformal radiotherapy where each beam was not only 
geometrically shaped, but also the intensity of radiation varied across the beam 
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(Figure 1.1). This permitted the delivery of dose distributions with concave isodose 
shapes (Bhide and Nutting 2010).  
a b c
 
Figure 1.1 Examples of simple methods of intensity-modulation a) wedge filter, 
b) Partial transmission block and c) tissue compensator. 
Reproduced (Nutting, Dearnaley et al. 2000) 
 
IMRT combines several intensity-modulated beams. The resultant isodoses are highly 
conformal, and uniquely can yield a concave distribution. IMRT therefore offers a 
significant advance in conformal therapy (Webb 1998), by improving conformality 
and reducing radiation dose to radiosensitive normal tissues close to the tumour even 
if they lie within a concavity in the PTV  (Brahme 1988).  
 
1.3.5.4 Production of intensity-modulated beams 
Intensity-modulated beams (IMB) can be produced in a number of ways (Webb 
1997): 
 
1.3.5.4.1 Metal compensators 
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A specifically manufactured metallic compensator is milled or moulded so that a 
variable thickness of the absorber is presented before the radiation beam. Production 
of compensators is relatively simple but expensive and time consuming. They are 
heavy and may be difficult to position accurately in the linear accelerator head. In 
practice this limits the number of IMB that can be delivered (Webb 1998), and this 
method is rarely used in current clinical practice. 
 
1.3.5.4.2 Multiple static fields (MSF) 
Each treatment field is divided into several smaller segments or sub-fields which are 
delivered sequentially (the “step and shoot” method). Each segment shape is defined 
by a multi-leaf collimator or shaped blocks. The addition of several segments 
produces an IMB. This type of IMRT can be delivered with technology already 
available in centres using an MLC to treat patients with 3DCRT, and is currently 
being used in Europe and the United States to treat patients with cancer of the 
prostate, head and neck, lung, breast, liver, brain, and other sites (Boyer and Yu 1999) 
(De Neve W 1996) (Eisbruch, Marsh et al. 1998). The current use of these techniques 
is based on observed dosimetric advantages as well as early reports of encouraging 
clinical outcomes (Eisbruch, Ship et al. 1996; Eisbruch, Marsh et al. 1998; Zelefsky, 
Leibel et al. 1998). To produce the required conformality, four to nine beam 
directions may be required depending on the complexity of the Planning Target 
Volume (PTV) (Boyer and Yu 1999) (De Neve W 1996) (Eisbruch, Marsh et al. 
1998). Each field may consist of three to twenty sub-fields which are delivered in 
succession (Figure 1.2). 
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Figure 1.2 The generation of an intensity-modulated beam by addition of multiple 
static fields 
 
For highly modulated beams, the total number of monitor units delivered per beam is 
often much higher than for conventional radiotherapy. These factors increase 
treatment time from around ten minutes for a conformal treatment delivery to fifteen 
to twenty-five minutes for IMRT (De Neve W 1996). Higher dose rates and 
optimisation of the sequence of delivery of segments have been used to minimise 
treatment times (De Neve W 1996). Physical problems with the use of an MLC to 
define segments include accuracy of MLC leaf placement, interleaf radiation leakage, 
the tongue and groove effect, and the accuracy of delivering small numbers of 
monitor units to some segments (Hansen and Evans 1998). 
 
1.3.5.4.3 Dynamic MLC (dMLC) 
Modulation of beam intensity by pairs of moving MLC leaves characterises this 
technique (also known as the “sliding window” technique). The IMB is constructed 
from a series of one-dimensional IMB formed by the differential speed profile of the 
+
+
+
+
=
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leading and trailing MLC leaves (Figure 1.3)(Convery and Rosenbloom 1992) (Stein, 
Bortfeld et al. 1994). Each leaf pair in the MLC leaf bank moves through a series of 
control points determined by an interpreter which converts the required intensity 
distribution into speed profiles for each leaf pair (Boyer and Yu 1999). 
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Figure 1.3 The delivery of an intensity-modulated beam using a sliding window 
technique 
 
Delivery times are quicker than for multiple static fields; typical delivery time for a 
five-field prostate treatment is 14 minutes (McNair, Adams et al. 2003). The leaf 
movements of the MLC during treatment must be accurate, as these produce the IMB. 
Leakage and transmission of radiation between or through MLC leaves must be taken 
into account in the dose calculation. Leakage occurs both between adjacent leaves, 
and between the ends of opposing leaf pairs. MLCs produced by different 
manufacturers vary greatly in this respect. Transmission of radiation through MLC 
leaves is less than 1.5-2% although larger transmission of up to 2.5-3% have been 
measured at the interlocking leaf edge (Galvin, Smith et al. 1993),  (Jordan and 
Williams 1994). The phenomenon known as the “tongue and groove” effect is 
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clinically significant in that it can cause tumour overdose or underdose (Sykes and 
Williams 1998), but can be removed by “synchronisation” (van Santvoort and 
Heijmen 1996; Webb 1997). 
 
 
Figure 1.4 The generation of a concave dose distribution from the summation of  
several intensity modulated beams. Reproduced from Nutting et al 2000 
 
Dynamic leaf movement during the treatment delivery, combined with continuous 
arcing of the gantry is known as intensity-modulated arc therapy (IMAT) (Yu 1995; 
Boyer and Yu 1999). This technique has the advantages of quick treatment time (5-10 
minutes), and may allow the use of fewer intensity levels than dMLC. IMAT is 
currently being implemented in many radiation oncology departments (Yu and Tang 
2011). 
 
Radiation
Intensity
Distance across beam
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1.3.5.4.4 Tomotherapy 
Tomotherapy describes IMRT techniques which irradiate the target slice by slice. The 
NOMOS Corporation developed the first commercially available tomotherapy 
machine, the Multivane Intensity Modulating Collimator (MIMiC) which was used in 
several centres in the United States (Carol, Grant et al. 1996; Grant and Woo 1999). 
A helical tomotherapy device was designed by Mackie (Mackie, Holmes et al. 1993) 
and is now in widespread use throughout the USA and Europe (Mackie, Balog et al. 
1999) (Burnet, Adams et al. 2010).  
 
1.3.6   Role of IMRT in head and neck cancer 
In head and neck radiotherapy there are many clinical situations where radiosensitive 
normal tissues lie within a concavity surrounded by the planning target volume 
(PTV). The treatment of patients with tumours of the larynx, pharynx, or thyroid are 
good examples. The clinical target volume (CTV) often includes a midline target, and 
bilateral cervical lymph nodes, producing a horseshoe-shaped PTV with the spinal 
cord within the concavity (De Neve W 1996). Homogeneous irradiation of these 
PTVs to radical doses (50-66 Gy) with conventional external-beam radiotherapy is 
difficult. Typically parallel-opposed photon portals are matched to electron beams. 
This technique leads to dose inhomogeneity at the photon-electron match-line, and 
may under dose the posterior cervical and deep cervical lymph nodes close to the 
spinal cord. Such under dose may result in failure to achieve local tumour control. 
This shape of PTV can be treated homogeneously using IMRT without the need for 
electrons (Figure 1.4). The dose to the spinal cord can be kept well within tolerance 
(De Neve W 1996) and permits tumour dose escalation (Figure 1.5).  
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While there were many reasons to expect good outcomes with IMRT in the head and 
neck there were also many unknown factors and some potential risks. First, IMRT 
was a complex technique to plan and deliver where small errors in planning or 
treatment delivery could lead to failure to deliver adequate dose to the tumour risking 
tumour recurrence. Second, the techniques of efficient delivery were unknown. Third, 
the use of multiple beams led to the deposition of larger areas of low dose irradiation 
than conventional radiotherapy and the consequences of this were unclear. There 
were particular risks about the effects of low dose radiation on second malignancy, 
and on growth of soft tissue and bone in paediatric cancer patients. 
 
 
Figure 1.5 An IMRT dose distribution to treat the thyroid bed and adjacent lymph 
nodes (solid red) while sparing the spinal cord (blue) in a patient with thyroid 
carcinoma. 
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From the above, it can be seen that head and neck cancer represents an ideal model 
system for testing IMRT in the clinic and to investigate the concerns expressed above. 
Several factors are relevant here. First, conventional and 3DCRT as practiced in head 
and neck cancer are associated with significant toxicity due to irradiation of normal 
tissues close to the target volume. IMRT using highly conformal dose distributions 
and ability to generate concave dose distributions should translate into reduction in 
organ at risk doses and reduced toxicity. Second, the ability to reduce the volume of 
normal tissue to be irradiated allows the opportunity to deliver higher radiation doses 
in an attempt to increase local tumour control. The next section outlines a program of 
work to implement IMRT at the RMH, the first centre to use this technique in the UK, 
and then to develop research protocols to answer the questions as to whether IMRT 
can reduce toxicity and improve tumour control in patients with head and neck 
cancer. 
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1.4 Thesis Road Map 
In Chapter 2, I seek to answer the first question posed in the title “Can intensity-
modulated radiotherapy be used to reduce toxicity in head and neck cancer patients?” 
First, I discuss an evaluation of our patient immobilisation system which needed to be 
assessed before treating head and neck cancer patients with IMRT at RMH (paper 1). 
At the same time, I performed an evaluation of the role of neck irradiation with IMRT 
(paper 2). Radiotherapy departments are usually very busy so there were initial 
concerns as to how efficient the new technique would be within the RMH 
radiotherapy department. A time and motion study is presented to determine the 
additional resources required to deliver IMRT (paper 3). Paper 4 presents an analysis 
of two tumour types where IMRT was tested through planning studies. Once these 
issues had been resolved, we started IMRT at RMH. In the UK we aspire to practice 
evidence-based medicine based on randomised controlled trial (RCT) data. In 2003, I 
was successful in my bid to win a clinical trial grant from Cancer Research UK to 
carry out a RCT called PARSPORT to evaluate whether parotid gland-sparing IMRT 
could lead to a reduction in long-term xerostomia in head and neck cancer patients. In 
order to do this, I needed to develop IMRT protocols which could be used in multiple 
UK radiotherapy departments. Papers 5 and 6 describe the process of national 
implementation and quality assurance required for the trial. Finally in paper 7, I 
present the results of the randomised trial which was published in Lancet Oncology in 
2011. The impact on international head and neck radiotherapy practice are discussed. 
 
In Chapter 3, I seek to answer the second posed question “Can IMRT improve tumour 
control in patients with head and neck cancer?” I chose to study tumours arising in 
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the larynx and hypopharynx as these tumours were associated with poor levels of 
local control and also were tumour sites where organ preservation was key for 
maintaining the normal functions of speech (larynx cancers) and swallowing 
(hypopharynx cancers). Three papers are presented. Initially I carried out a theoretical 
planning study to assess if the delivery of additional dose, to improve local tumour 
control, was possible using IMRT (paper 8). Radiation dose escalation is a potentially 
dangerous treatment approach as the extra radiation dose may cause an increase in 
damage to normal structures such as cartilage, bone or soft tissues close to the 
tumour. In oncology, we typically use Phase I studies to determine the safety of new 
treatments in patients. I, therefore, designed a Phase I radiation dose escalation trial 
for patients with tumours of the larynx and hypopharynx and thyroid. Papers 9 and 10 
describe the acute and late side effects in the larynx and hypopharynx trial. As a 
consequence of these results, I designed a second RCT (ARTDECO) to compare 
standard dose radiation with escalated dose radiation in this patient group to test the 
hypothesis that increase in radiation dose would lead to increase in tumour control 
and possible overall survival in head and neck cancer patients.  
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2.1 Introduction 
Radiotherapy for head and neck cancer is a complex process. To achieve high quality 
treatment, it is important to achieve a series of individual goals. These are often 
referred to as the “radiotherapy chain” where each link has to be strong to achieve a 
good treatment outcome.  
 
 
Figure 2.1 the Radiotherapy Chain 
 
The links in the chain are accurate immobilisation of the patient, good quality CT 
imaging, accurate definition of the target volume and OARs, high quality treatment 
planning, accurate treatment delivery and quality assurance of the treatment delivery. 
 
2.2 Review of Immobilisation (paper 1) 
When we started the head and neck IMRT program the radiotherapy chain had to be 
revisited. One of the main differences between conventional radiotherapy and IMRT 
is the steep dose gradients that are produced around tumour targets and OARs seen on 
IMRT plans. It is, therefore, critical that the immobilisation of the patient is as 
accurate and reproducible as possible to ensure that the deposition of radiation dose is 
Chapter 2 
45 
 
 
correct. Furthermore, the performance of the immobilisation system needs to be 
known in order to add appropriate margins to the Clinical Target Volumes (CTVs) 
when generating Planning Target Volumes (PTVs). 
 
Paper 1 reports the assessment of a customised immobilisation system for head and 
neck IMRT. Figure 1 in that paper shows the new 4 point immobilisation shell. It 
differed from our previous immobilisation shell in that it extended down to the 
shoulders and over the skull vertex and had 4 points of attachment rather than the 
traditional 2 points. This study showed the accuracy of daily set up in 20 patients 
measured using 354 electronic portal images. In this study, we demonstrated that 94% 
of translational displacements were ≤ 3mm, and 99% ≤ 5mm. Looking back at this 
study, the findings have been robust. The overall systematic error was 0.9 mm (±1.0 
SD) in the right-left, 0.7 mm (±0.9 SD) in the superior-inferior, and -0.02 mm (±1.1 
SD) in the anterior-posterior directions. The corresponding SDs of the random errors 
were ±0.4, ±0.6, and ±0.7 mm. We used the Van Herk formula (van Herk, Remeijer 
et al. 2000) to calculate the estimated CTV-PTV margins and found them to be 2.9, 
2.6 and 3.3 mm respectively. Based on this we adopted a 3 mm CTV-PTV margin for 
our head and neck IMRT. The use of electronic portal imaging in this study was a real 
advantage. First, it allowed computer-assisted matching – much more accurate than 
working from traditional portal films, and second, it also calculated the errors within 
the computer program reducing the chance of operator error. One area of concern is 
that many centres delivering IMRT have adopted 3 mm margins based on our data 
without doing their own departmental study. Between one radiotherapy centre and 
another there are many potential differences in equipment which could impact on the 
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performance of an immobilisation system, such as couch stiffness, use of a head 
board, type of material used to make the shell, type of attachment of the shell to the 
couch, and skill of the mould room staff. For these reasons, I would encourage each 
centre to carry out their own assessment of their systems rather than adopting 
published data. This paper sets out the methods which might be adopted by a centre 
wishing to make these measurements for themselves. 
 
As technology has advanced, current studies have shifted away from imaging the 
bone tissues with portal imaging, towards imaging the soft tissues, or even the tumour 
itself with MV/kV cone-beam CT (Bhide and Nutting 2010). This has led us to realise 
that while the bones of the head and neck region may be immobilised during a course 
of radiotherapy, the soft tissues may change considerably during treatment. For 
example, several authors have recently demonstrated that the parotid salivary glands 
shrink and their centre of gravity moves medially during the course of radiotherapy 
(O'Daniel, Garden et al. 2007), the external contour of the patient may also change 
significantly due to weight loss and, of course, the tumour itself may shrink 
considerably during a course of treatment. At the present time it is not clear exactly 
what effects these factors are likely to have on the delivered dose to the tumour and 
the OAR. In particular it is not known whether the small dose differences seen in 
studies are sufficient to affect patient outcomes. In a study in our centre (Bhide and 
Nutting 2010), we demonstrated that most of the soft tissue changes occur between 
the planning scan and the second week of radiotherapy.  Theoretically, it is possible 
to adapt your radiotherapy plan during the course of treatment to take these changes 
into account. This approach had been called “adaptive radiotherapy”, but in practice 
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this process is not in widespread use because re-planning is so time consuming. Most 
centres, including mine, would only re-plan a patient’s treatment if the 
immobilisation system started to fail e.g. due to severe weight loss causing positional 
error of >3 mm. 
 
2.3 How to treat the neck nodes: IMRT or Conventional technique? (Paper 2) 
In 2001, there were fewer than 10 academic centres worldwide treating head and neck 
patients with IMRT and reporting the implementation or results of the technique 
(Nutting, Rowbottom et al. 2001). The most common head and neck tumour sites 
being treated were tumours of the pharynx, where IMRT was being used for parotid 
gland sparing. Tumours of the pharynx have a high risk of nodal metastasis to the 
anterior cervical lymph node chains which need to be included in the target volume 
for a radiation treatment. Two schools of thought existed. Some centres, such as 
University of Michigan and Memorial Sloan-Kettering, treated the primary tumour 
and the neck with IMRT (Marsh, Eisbruch et al. 1996).  Advantages were that IMRT 
provided a more conformal plan and allowed better coverage of the lymph nodes. 
Disadvantages were that because of the use of multiple fields, some of the OAR were 
included in the low dose bath which exposed organs such as the larynx, oesophagus 
and spinal cord to higher radiation doses than the conventional anterior neck field 
with midline shielding.  The second school, mainly centres on the west coast of the 
US such as UCSF, preferred to use IMRT fields to treat the primary tumour in the 
oropharynx and then match to a conventional anterior neck field below the hyoid 
(Chao, Low et al. 2000). Stated advantages were that it minimised dose to the OARs, 
especially the larynx, reduced treatment time and complexity and, for some treatment 
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machines with small MLC field length, it was a necessity. Disadvantages were that 
the conventional anterior neck field was not conformal and risked underdosing some 
of the lymph node groups. 
 
Paper 2 represents an attempt to study the latter point and determine the optimal 
technique for cervical node irradiation in this setting. With conventional radiotherapy, 
typically either a single anterior photon field or anterior and posterior parallel-
opposed fields were used. Single anterior fields were known to under dose the 
posterior cervical nodes, but these were only at very high risk in patients with 
carcinoma of the nasopharynx. Moderate risk was seen in patients with carcinoma of 
the oropharynx, larynx and hypopharynx (Candela, Kothari et al. 1990). There was 
considerable variation in technique between centres (Nowak, Wijers et al. 1999). A 
consensus statement had recently defined a method of localisation of cervical lymph 
nodes using CT imaging (Gregoire, Coche et al. 2000). The methods of target volume 
definition had been developed by Wijers (Wijers, Levendag et al. 1999) and Nowak 
(Nowak, Wijers et al. 1999). This study systematically studied several techniques of 
cervical node irradiation using the cervical node volume definitions to determine 
PTVs. Conventional radiotherapy techniques (CRT) using single and opposed fields 
were studied in this paper using moderate (6 MV) and high (10 MV) energy photons. 
The use of IMRT to improve dose homogeneity in the neck was also assessed as a 
second part of this study. 
 
The main findings of this study were that IMRT using opposed fields gave the best 
dose distributions with optimal mean dose and dose homogeneity, and that this was 
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better than any of the conventional techniques either using opposed beams of either 6 
or 10 MV. This was particularly important for cervical lymph node levels II and V 
which extend posteriorly in the neck as shown in Figure 5 of the paper. As a 
consequence of these data, we concluded that IMRT should be used to treat the 
cervical lymph nodes as part of our treatment program.  
 
One of the benefits of this research was the clinical algorithm I developed. The most 
common clinical scenarios are shown in the algorithm in Figure 6. These include 
irradiation of the whole cervical lymph node chain (levels I-V), or selective nodal 
irradiation. The most common regions for selective anterior-posterior irradiation are 
levels III and IV, or IV alone, when the upper neck is included in lateral fields which 
also irradiate the primary tumour site. If irradiation of the posterior (level V) nodes or 
upper deep cervical nodes (level II) is required, then the opposed field IMRT 
technique with either 6 MV or 10 MV energy gave the best target coverage and dose 
homogeneity which should maximise tumour control probability (TCP) and minimise 
normal tissue complication probability (NTCP). This is due to the posterior position 
of level V and the posterior part of level IIB.  
 
If the aim is to irradiate electively level III and IV but not II or V, (e.g. when the 
primary tumour and upper neck are irradiated with lateral fields), then single field 
CRT with 6 MV or 10 MV produced the best target coverage and IMRT has no 
significant additional benefit. If level IV is to be irradiated alone, then 6 MV or 10 
MV single field CRT is the simplest technique. 
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In practice, the overriding priority for irradiation of most pharyngeal cancers is to 
prevent radiation-induced xerostomia by sparing the parotid glands. The technique 
used for this is described in paper 5, but typically uses 5-7 non-opposed radiation 
beams to irradiate the tumour targets. This beam arrangement is not the same as those 
anterior and posterior beam position techniques presented in paper 2, so some 
additional aspects of technique were developed to protect the midline structures of the 
anterior neck from irradiation. This comprised a non-anatomical avoidance structure 
which was constrained to doses of less than 30 Gy and thus minimized the dose to the 
larynx and cervical oesophagus as much as possible (see paper 5). 
 
2.4 Time and motion studies in IMRT: delivering a complex treatment in a busy 
department cost and staff implications (paper 3) 
With the introduction of more complex treatments such as IMRT, the potential 
increased use of specific resources, such as time and staff, needed to be assessed and 
justified. At the time of publication of paper 3, an increasing number of radiotherapy 
departments in Europe were aiming for clinical implementation of IMRT and initial 
experience from other centres was becoming available (Adams, Convery et al. 2004; 
Boehmer, Bohsung et al. 2004; Teo, Ma et al. 2004; Venencia and Besa 2004; Zhu, 
Schultz et al. 2004) . However, increased workload remained a major concern in the 
UK. There were little data available regarding planning and treatment times. These 
were important for the acceptance of IMRT from both the patients’ perspective and 
ultimately for integration of a change in practice into the routine clinical workload. 
At the Royal Marsden Hospital, our team had adopted single phase IMRT delivery to 
reduce planning and treatment times (Butler, Teh et al. 1999; Wu, Mohan et al. 2003). 
Chapter 2 
51 
 
 
In paper 3 I present the comparison of our novel single phase IMRT technique 
(described below and in Paper 5) to the previously used conventional radiotherapy 
technique. Conventional treatment required multiple portals and sequential field 
reductions. Additional significant gains were anticipated in patients with advanced 
head and neck cancer eliminating the complexity of photon and electron field 
matching and multiple phase treatments (Clark, Bidmead et al. 2004). 
In the radiotherapy department, we measured time taken for clinicians, radiographer 
and treatment planners to produce plans for conventional radiotherapy and IMRT. 
The detailed description of the tasks is given in paper 3.  
 
The main findings of this study were that IMRT planning and delivery took longer 
than conventional treatment planning. Clinician time was increased by 2.3 hrs for 
IMRT, radiographer time was reduced by 1.6 hrs, and physics time was increased by 
4.9 hrs compared to conventional radiotherapy. A learning curve was observed over 
the first 11 patients treated both for patient-specific QA and duration of treatment 
time (see paper 3 Figures 2 and 3). 
 
Since this paper was published in 2005, there have been significant advances in 
IMRT techniques. First, greater computational power is available for planning 
computers which are also running more efficient optimisation software. This has now 
shortened planning time to a maximum of 60 minutes per case (Bidmead, personal 
communication 2011). Second, more rapid delivery techniques are now available. At 
its most simple, this relates to more accurate and robust MLC design, but a new 
technique of intensity-modulated arc therapy – IMAT;  (Yu and Tang 2011)  has now 
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come into common usage. This is an IMRT technique where the gantry of the linear 
accelerator rotates during IMRT delivery. The advantages of this technique are the 
reduction in delivered monitor units and, therefore, faster treatment delivery 
compared to the standard fixed field IMRT used in our study. Recent papers suggest 
that the delivery times may be almost halved by IMAT compared to IMRT (Lee, 
Chao et al. 2011; Stieler, Wolff et al. 2011). Another question is what is the level of 
quality assurance required for IMRT plans? In the early days of IMRT, it was advised 
to perform quality assurance on each patient’s treatment plan. This would include 
measurement of dose deposition by ion chamber and thermo luminescent dosimeters 
(TLDs) inside a phantom. This was a complex and time consuming procedure, 
particularly for physics staff in the radiotherapy department. Nowadays, in 
departments experienced in the IMRT technique a QA “sampling” process is used 
where typically 1 in 5 plans are subjected to a full QA measurement by delivery of 
the treatment to a phantom, and a pre-treatment independent monitor unit check is 
used for the remaining cases (Georg, Nyholm et al. 2007). These advances in QA 
techniques have substantially reduced the time required to prepare an IMRT plan in 
centres where large numbers of patients are treated with IMRT.  
  
Clinician time spent performing target volume delineation (TVD) remains an issue at 
present, with TVD taking anything from 1-4 hours. Auto-contouring software has 
been assessed, but at the present time is not sufficiently accurate for routine clinical 
use (Wang, Garden et al. 2008) .  
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The findings of this paper have been used by the National Cancer Action Team 
(NCAT) to develop UK national recommendations as to the resources required for 
UK radiotherapy departments to implement IMRT for patients (Department of Health 
2011). 
 
2.5 Prioritising what to treat with IMRT: the planning studies (paper 4) 
Radiotherapy planning studies offer the possibility to simulate radiotherapy treatment 
“in silico” for the purpose of identifying and quantifying potential improvements in 
outcome for one radiotherapy technique versus another (Nutting, Bedford et al. 2002) 
(Cardinale, Benedict et al. 1998; Eisbruch, Marsh et al. 1998; Khoo, Oldham et al. 
1999). Overall, I performed planning studies for several head and neck tumour sites. 
The planning studies for parotid gland IMRT (Nutting, Rowbottom et al. 2001; 
Rowbottom, Nutting et al. 2001), and thyroid IMRT (Nutting, Convery et al. 2001) 
were presented in my MD (res) thesis. In this section two further published planning 
studies are presented. First, I performed a study to see if IMRT could be used to 
reduce the optic nerve dose in patients with cancer of the maxillary sinus cancer 
(Adams, Nutting et al. 2001). This represented a particularly difficult challenge in 
treating this tumour site, and I thought that IMRT had the potential to reduce the risk 
of radiation-induced loss of vision. Second, I performed a study of parotid gland 
sparing in oropharyngeal cancer (paper 4) to assess the likely reduction in radiation-
induced xerostomia using the PARSPORT trial guidelines for TVD 
 
For both studies, actual patient data (CT scans) of the disease in question were 
imported into a treatment planning system (TPS). Target volumes and organs at risk 
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were localized, and different treatment techniques were applied. In both papers, 3-
dimensional conformal radiotherapy plans were compared to intensity-modulated 
radiotherapy plans.  
 
Descriptive statistics were used to compare dose-volume data for tumour targets and 
organs at risk using dose and volume to predict the chances of complications. Normal 
tissue complication probability (NTCP) was similarly modelled for the parotid gland 
in paper 4. This type of methodology is still in widespread use in the current 
literature. The use of these techniques on small groups of patients rapidly provides 
information as to which technique is superior and provides some estimate of the size 
of the clinical benefit that might be anticipated. Theoretical planning studies have the 
advantage that they are relatively quick to perform, and statistically easy to analyse. 
The use of repeated testing of a variety of techniques in one individual allows the use 
of the statistically efficient paired t-test for normally distributed data and the Mann 
Whitney U test for non-normal data distribution. The use of planning studies does, 
however, have some drawbacks. The models used for NTCP are still relatively 
experimental, and while they may help rank plans in order of quality, the absolute 
value of NTCP is probably not very accurate. Furthermore, deciding which plan is the 
best out of a series is not always straightforward and the investigator may have to be 
prepared to weigh up the “pros and cons” of each dose distribution. This process may 
be biased by the clinician’s opinion as to what the clinical priorities or goals are for a 
particular tumour site.  
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The planning study of maxillary sinus cancer demonstrated that IMRT plans 
produced consistently lower doses delivered to the optic nerve and chiasm. The 
average maximum optic nerve dose was 56.4 Gy with IMRT compared to 65.7 Gy 
with 3DCRT plans. This difference of over 9 Gy was clinically important at it meant 
that patients with this tumour type could be safely offered a higher prescribed 
radiation dose to their tumour which should translate into improved local tumour 
control. IMRT plans also produced lower radiation doses to the brain and salivary 
gland tissue. These effects were of less clinical importance, but may reduce the risk of 
other side effects of radiotherapy. 
 
The planning study for oropharyngeal cancer was more complex. Xerostomia is the 
most prevalent long-term complication following radiotherapy for head and neck 
cancer in patients who require bilateral neck irradiation and is associated with 
significant deterioration in the patient’s QoL (Jensen, Hansen et al. 1994; Bjordal and 
Kaasa 1995; Wijers, Levendag et al. 2002). By 2001, IMRT had been shown to 
achieve significant reductions in the dose delivered to the parotid glands and several 
small single institution phase 2 studies had suggested lower xerostomia rates and 
improvements in quality of life (QoL) (Ship, Eisbruch et al. 1997; D'Hondt, Eisbruch 
et al. 1998; Eisbruch, Marsh et al. 1998; Eisbruch, Dawson et al. 1999; Kuppersmith, 
Greco et al. 1999). Most of these early clinical reports failed to give clear protocols 
for TVD, making reproducibility difficult. The ability to reduce radiation dose to the 
parotid gland was largely determined by its proximity to the PTV (Chao, Low et al. 
2000) and, therefore, is significantly affected by differences in TVD. 
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I thought that in the UK there was an opportunity to carry out a multi-centre 
randomised controlled trial of parotid-sparing IMRT versus conventional 
radiotherapy. Agreement was reached amongst the trial participants as to the methods 
of TVD. The CTV definition guidelines used in this paper are important. This was the 
first time that primary tumour target outlining guidelines for a trial had been 
published in the literature. Key features were that I recommended that the entire 
oropharyngeal mucosa was included in the CTV 1, from the superior aspect of the 
soft palate to the hyoid bone. Laterally, on the involved side, the CTV1 extended to 
the mandible and included the ipsilateral parapharyngeal space. The contralateral 
parapharyngeal space was spared (see Figure 1 in paper 4). I used data from several 
sources to come to these conclusions. First, the data from pathological studies 
suggests that submucosal spread of squamous cell carcinoma is common and can 
extend over 1cm from the clinical or radiologically visible tumour edge. This 
phenomenon accounts for the high rates of local recurrence from partial pharyngeal 
surgery. Second, conventional radiotherapy techniques based on sound anatomical 
principles had irradiated the whole oropharynx for tumours approaching the midline 
for decades, and the local control rates with this technique were well described. 
Moving away from this principle of treatment risked higher levels of local tumour 
recurrence in the IMRT arm. 
 
These guidelines differ from other researchers e.g.(Chao, Low et al. 2000), who 
prefer to use anatomically grown CTV from the GTV. In reality, the two different 
approaches lead to similar CTVs for all but very small primary tumours. Figure 1 and 
2 in paper 4 demonstrate typical target volumes. For the outlining of CTV 2, the 
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elective lymph node volumes, we used the then recently published DAHANCA, 
EORTC, GORTEC NCIC, RTOG consensus guideline, but with a British 
modification, namely additional inclusion of the supraclavicular fossa down to the 
clavicles. This was done as UK oncologists felt that these areas were occasionally 
seen as sites of tumour recurrence. Since the PARSPORT trial, I have removed this 
“British modification” and reverted to the standard international consensus for one of 
the subsequent trials – e.g. the ART DECO protocol.  
 
Conventional plans and IMRT plans were constructed as detailed above. With 
conventional plans, I sought to use the type of treatment planning in common UK 
clinical practice, such that any potential improvements with the IMRT plans could be 
compared to the UK standard of practice. This has sometimes been criticised because 
at the time of publication some radiotherapy departments in Europe and the USA 
were already using more complex treatment methods (e.g. 3-dimensional conformal 
radiotherapy, and forward-planned IMRT) to treat these patients. For a particular 
country, with an established standard of care for cancer treatment I think it is 
important that for a clinical trial, that “standard” treatment arm of the trial should 
represent the prevalent national practice at the time of trial design. Strict planning 
requirements were set for plan assessment as given in table 1 of paper 4. 
 
This planning study was unusual in that the endpoint of the study was the predicted 
normal tissue complication probability (NTCP) (Kutcher, Burman et al. 1991) for 
salivary gland function. 
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At the time, there were two parameter sets proposed in the literature (see Table 2.1), 
and so we had to calculate NTCP using both parameter sets using the BIOPLAN 
software (Sanchez-Nieto and Nahum 2000) .  
 
 Eisbruch et al. Roesink et al. 
Parameter TD50 m TD50 m 
Mean 28.4 0.18 39 0.45 
95% confidence 
interval 
25-34.7 0.1-0.33 34-44 0.33-0.65 
 
Table 2.1 Eisbruch and Roesink parameters for parotid NTCP 
 
The main results of paper 4 were that, for the PTVs, the dosimetric goals were 
achieved with adequate target coverage of the PTV1 and 2, and that spinal cord 
tolerance was observed (Figure 3 paper 4). However, for IMRT plans the dose to the 
parotid glands, especially the contralateral parotid, were significantly reduced, and 
the dose homogeneity to PTV2 was significantly better. 
 
The calculated NTCP values are shown in Table 2.2. Both parameters showed highly 
statistical differences in predicted NTCP, however, as will be seen later in this 
chapter, neither parameter set was accurate in predicting subsequent clinical 
outcomes. 
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Table 2.2 Mean (± 1 standard deviation) NTCP values for IMRT vs. 3DCRT 
 
Looking back, this area of head and neck oncology practice has moved forward 
significantly since the publication of paper 4 in 2007. Studies have shown a wide 
variety of target volume delineation amongst clinicians (Rasch, Steenbakkers et al. 
2005). In the early days of parotid gland-sparing IMRT, there was concern about the 
risk of recurrence in the spared tissue around the parotid. This risk was uncertain at 
the beginning of the trial and was included as a risk in the patient information sheet 
for the PARSPORT trial. It was one of the aspects of the trial that both myself and the 
patients were concerned about. A review of the literature in this area shows that only 
one recurrence has been reported in the spared tissue adjacent to the parotid gland 
(Chao, Ozyigit et al. 2003; Eisbruch, Marsh et al. 2004) (Bussels, Maes et al. 2004) . 
  
Nasopharyngeal cancer is rare in the UK, but represents a specific case where parotid 
gland sparing may be considered. IMRT is commonly used in Hong Kong and China 
where this cancer type is most prevalent, but occasional tumour recurrences have 
been seen in the parotid gland, especially in cases where extension of tumour along 
the Eustachian tube allows lymphatic drainage to the intraparotid nodes. 
 
 
Eisbruch et al (1999) Roesink et al (2001) 
 
IMRT 3D-RT p IMRT 3D-RT p 
Contralateral parotid 22.3 ± 10.3 100.0 ± 0.0 0.00007* 20.1 ± 3.5 98.7 ± 2.7 0.000004* 
Ipsilateral parotid 100.0 ±  
0.0 
100.0 ± 0.0 NA 92.2 ± 11.0 99.6 ± 0.6 0.2 
(p<0.05) *Statistical significance (P <0.05)  using the Student t test 
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In the University of Michigan experience, Eisbruch et al (2004) found no recurrences 
in the contralateral neck, cranial to the sub-digastric nodes and the authors felt that 
the crossing of the posterior belly of the digastric muscle and IJV was a safe superior 
margin for the contralateral level. So the consensus emerged that it was safe to place 
the margin of the upper neck node fields at the bottom of the transverse process of C1 
(Gregoire, Levendag et al. 2003) in the node negative neck and where there is no 
specific clinical indication to include the jugular fossa (Prins-Braam, Raaijmakers et 
al. 2004).  
 
In our study, parotid-sparing IMRT achieved reductions of the mean dose to the 
contralateral parotid gland to 22 Gy, below the threshold suggested by Eisbruch et al 
(1999) for preservation of function. We also found reductions in the volume of 
ipsilateral parotid irradiated to 45 Gy and 60 Gy. Roesink et al (2001) reported some 
recovery when 40-80% of the gland was irradiated to 35-45 Gy and it may be that 
these observed reductions in volume irradiated could possibly translate to a small 
recovery of function in the ipsilateral parotid gland. 
 
Calculated NTCP values for the contralateral parotid with PS-IMRT were 20-22% 
suggesting that xerostomia may be significantly reduced but not eliminated (Eisbruch, 
Dawson et al. 1999) (Roesink, Moerland et al. 2001). This general observation was 
subsequently disproved and is discussed later in this chapter.  
 
Very recently it has become apparent that regions of the human parotid gland are not 
homogeneous in their ability to secrete saliva. Animal data from rat parotids (van 
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Luijk, Faber et al. 2009) suggests that the cranial and caudal compartments of the rat 
parotid contribute differently to saliva production. Recent data from our group 
suggest that this is analogous to the deep and superficial lobes of the human parotid 
gland (Miah 2011). 
 
If these two planning studies are compared and contrasted, we start with the following 
two observations: 
1. For Paranasal sinus cancers, IMRT reduced the dose to the optic nerve and 
may reduce the risk of radiation-induced optic nerve damage and blindness 
(Adams, Nutting et al. 2001). 
2. For oropharyngeal cancers, IMRT can be used to reduce the dose to the 
parotid salivary tissue and that the IMRT technique should, in theory, allow 
recovery of parotid gland function such that xerostomia may be reduced or 
avoided (paper 4). 
 
While “in-silico” planning studies offer the potential to test possible benefits of one 
dose distribution against another, the results of such studies are not sufficient to 
change practice. For this, actual clinical outcome data are required, ideally in the 
context of a well designed randomised controlled clinical trial. The planning study is 
helpful in determining the likely size of a clinical benefit (for example the differences 
in NTCP for parotid in paper 4) which may help guide sample size calculations for 
trials.  
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Of the two clinical scenarios given above, I considered that they represented two very 
different scenarios in terms of their potential to develop into practice-changing 
clinical trials. 
First, xerostomia is an important long-term side effect of radiotherapy to the head and 
neck region which can be measured subjectively, objectively and with quality of life 
instruments (Jensen, Hansen et al. 1994; Bjordal and Kaasa 1995; Wijers, Levendag 
et al. 2002). The complication is common and the disease site also prevalent in the 
UK. At the same time there were a number of potential risks with the IMRT. First, the 
tissue around the parotid gland was not going to receive a tumouricidal dose, and 
therefore there was concern that tumour recurrences might be seen in the area close to 
the parotid gland. Second, the addition of multiple intensity modulated beams each 
day over a period of 6 weeks may not always deliver a homogeneous high radiation 
dose to the tumour and therefore tumour control might be compromised. Third, the 
delivery of low dose radiation to other tissues may have unexpected long-term 
consequences.  I, therefore, decided to design a randomised controlled trial of 
conventional technique vs. IMRT to test whether IMRT would reduce the xerostomia 
rates in patients. This trial (PARSPORT) will be detailed later in this chapter. All of 
the risks and potential benefits detailed above were included in the PARSPORT trial 
patient information sheet. 
 
By contrast, I did not think that it was possible to develop the theme of the maxillary 
sinus tumours into a randomised clinical trial. Radiation-induced optic nerve damage 
is a very serious late radiation side effect with a low predicted incidence which may 
take years to manifest (Martel, Sandler et al. 1997). In terms of trial design that would 
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mean a low number of events necessitating very large trial patient numbers over a 
long period of time. Second, paranasal sinus tumours are very rare such that any large 
randomised trial would not be feasible. Third, in paranasal sinus cancer, it would not 
be considered ethically appropriate to randomise patients to standard treatment arms 
which carried a risk of such serious late radiation complication as blindness.  
 
It has been stated that this last argument could also be applied to PARSPORT (i.e. 
how can you ethically randomise patients to receive an above-tolerance dose to an 
OAR?). My response has been that in order to advance our specialty and develop new 
techniques, it is required that randomised controlled trials should be used when 
possible. In retrospect, I still maintain that the decision for a randomised controlled 
trial was correct. It will be seen later in this chapter that 47 patients were randomised 
in the PARSPORT trial to receive conventional radiotherapy, and approximately 80% 
of them were rendered xerostomic as a consequence. The process of the trial allowed 
us to deliver evidence of the benefits of IMRT which now is being recommended for 
all patients in the UK, Europe and abroad as the standard of care. It also encouraged 
implementation of IMRT in UK centres, provided education and training. 
 
2.6 The PARSPORT trial: Preparations for a UK IMRT group and the 
challenge of delivering a high quality multicentre trial (paper 5 and 6) 
In 2002, I started to work on the design of a randomised controlled trial of 
conventional radiotherapy vs. IMRT. At that time, there were limited reports in the 
literature of the outcome of head and neck IMRT. 
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At the University of Michigan (UM), IMRT was used to spare salivary gland tissue in 
patients irradiated for head and neck tumours. PTV included the primary tumour, 
ipsilateral cervical lymph nodes, and contra-lateral cervical lymph nodes up to and 
including the sub-digastric node. If the contralateral parapharyngeal space and parotid 
gland were judged to be at very low risk of harbouring occult metastases, they were 
spared, as were the submandibular salivary glands (Eisbruch, Ship et al. 1996; 
Eisbruch, Marsh et al. 1998). Patients were treated with a forward-planned “step-and-
shoot” IMRT technique using multiple non-coplanar photon beams, and low-
weighted electron fields (personal observation UM 1999). A beams eye view facility 
was used to select beam orientations that avoided the parotid gland (Marsh, Eisbruch 
et al. 1996). Unstimulated and stimulated salivary flow was measured from each 
parotid gland before and after radiotherapy and then at three, six, and twelve months. 
In fifteen patients treated with this parotid-sparing technique, IMRT improved the 
minimum dose, and reduced dose inhomogeneity to the primary tumour and lymph 
node regions compared to standard three-field conformal plans. IMRT reduced the 
radiation dose to the contralateral parotid gland to 32% compared to 93% for the 
standard plan. Smaller, statistically significant, reductions in the dose to the oral 
cavity, contralateral submandibular gland, and spinal cord were also seen but are 
unlikely to be clinically significant. One to three months after irradiation, the mean 
stimulated salivary flow from the contralateral parotid gland was 60% (SD 49%) of 
pre-treatment measurements (Eisbruch, Ship et al. 1996). Longer follow-up of eleven 
of these patients showed that spared parotid glands, which received a mean dose of 
19.9 Gy, recovered 63% of their pre-treatment stimulated salivary flow rates at one 
year compared to only a 3% recovery for treated parotid glands which received 57.5 
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Gy (Ship, Eisbruch et al. 1997; D'Hondt, Eisbruch et al. 1998) (Table 2.3). At the 
time of this report, it was not clear what the relationship was between salivary flow 
rates (an objective measurement) and patient reported symptoms of dry mouth 
(subjective). 
 
 Spared parotid Treated parotid p value 
Pre-radiotherapy 0.40 ± 0.22 ml/min 0.36 ± 0.31 ml/min N/A 
Completion of RT 0.12 ± 0.07 ml/min 0.008 ± 0.02 ml/min 0.0004 
3 months 0.20 ± 0.21 ml/min 0.003 ± 0.01 ml/min 0.05 
6 months 0.24 ± 0.17 ml/min 0.006 ± 0.02 ml/min 0.001 
1 year 0.25 ± 0.02 ml/min 0.011 ± 0.03 ml/min 0.006 
  
Table 2.3 Mean stimulated salivary flow (± SD) after parotid-sparing IMRT 
 
An analysis of eighty-eight patients treated with parotid-sparing IMRT allowed 
correlation of radiotherapy dose with salivary flow measurements to produce dose-
response curves for parotid gland function. A mean dose threshold was found for both 
stimulated (26 Gy), and unstimulated (24 Gy) saliva flow rates, such that glands 
receiving mean dose below or equal to the threshold showed substantial preservation 
of the saliva flow following radiotherapy, which may continue to improve over time. 
By contrast, most glands receiving mean doses above the threshold produced little 
saliva and had no recovery over time (Eisbruch, Dawson et al. 1999). A subsequent 
published analysis did not reveal increased risk of nodal relapse in the vicinity of the 
spared parotid gland (Dawson, Anzai et al. 2000).  
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De Neve et al (1999) from the University of Gent reported the results of treatment of 
three patients with recurrent or second primary tumours of the nasopharynx, 
oropharynx, and hypopharynx with IMRT. All patients had been previously treated 
with radical radiotherapy; tumour dose 66-70 Gy, spinal cord dose 44-45 Gy, and had 
inoperable disease. An IMRT technique was used to re-treat the tumour (minimum 
target dose 48-65 Gy), with a concave dose distribution to avoid the brain stem and 
spinal cord (maximum spinal cord dose 21-34 Gy, maximum brainstem dose 67 Gy). 
Two patients achieved complete remission, but relapsed within one year of 
radiotherapy, and the other patient remained in partial remission seven months after 
treatment. No patient developed myelopathy, although the follow-up period was 
short. The same author has reported an IMRT technique for the irradiation of tumours 
in the neck which extend into the upper mediastinum. This technique has been used in 
the treatment of tumours of the thyroid, larynx and pharynx and would allow target 
dose escalation up to 70-80 Gy while restricting maximum spinal cord dose to 50 Gy 
(De Neve W 1996).  
 
Boyer  et al (1997) reported the results of a planning and delivery study where three 
patients with head and neck tumours were planned on the PEACOCK inverse 
planning system (now updated to CORVUS, NOMOS Corporation, Sewickley, PA), 
and the plan was delivered to a humanoid phantom using nine equispaced fields by a 
dynamic MLC technique. For a patient with nasopharyngeal carcinoma, 96% of the 
primary tumour PTV reached the goal dose of 72 Gy, although part of the gross 
tumour volume (GTV) received 90 Gy. A goal dose of 54 Gy was prescribed to the 
lymph node chains but 12% of this PTV was under dosed, with a minimum dose of 
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26.5 Gy. Parotid and spinal cord sparing were achieved with delivered doses below 
clinical tolerance. Similarly, for tumours of the larynx and ethmoid sinus, mean target 
doses were achieved and normal tissue structure sparing was successful, although 
target dose inhomogeneity was high. (Goitein and Niemierko 1996) have calculated 
that such dose inhomogeneity may lead to large reductions in the probability of 
tumour control. However, in comparison with standard techniques, the precise 
location of lower dose regions and effects, for example, of patient movement as well 
as the accuracy of the planning algorithm need to be considered in determining the 
desired tolerance of such dose inhomogeneities. 
 
The first clinical report of twenty-eight patients with a spectrum of head and neck 
tumours treated with the MIMiC tomotherapy apparatus (NOMOS Corporation, 
Sewickley, PA) has been published from the Baylor College of Medicine (Butler, Teh 
et al. 1999; Kuppersmith, Greco et al. 1999) . Ten patients were treated for tumour 
recurrence after previous conventional radiotherapy, and in eighteen patients IMRT 
was part of the primary treatment. Patients were initially immobilised using an 
invasive fixation device (Talon, NOMOS Corporation, Sewickley, PA) which 
attached to screws placed in the inner table of the skull vertex, although currently half 
of their patients are immobilised in a standard thermoplastic mask (Engler, Curran et 
al. 1994). After CT scanning, inverse treatment planning was performed with the 
objective of minimising the dose to parotid glands, brain, orbits, optic nerves, and 
brainstem, depending on tumour site. Treatment was well tolerated with acute toxicity 
equivalent to conventional radical radiotherapy. A high degree of parotid sparing was 
demonstrated in suitable patients, with less than 20% of the total parotid volume 
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receiving greater than 20 Gy. Clinical follow-up of these patients is short, and 
although only one of twenty patients treated definitively has recurred locally, long-
term results are not yet available. 
   
Using the above data, I designed a simple randomised controlled trial where patients 
at high risk of radiation-induced xerostomia would be randomised to either standard 
technique radiotherapy or IMRT. The primary end-point was the incidence of high 
grade xerostomia reported by patients using the LENT-SOMA (late effects of normal 
tissue – subjective, objective, management, analytical) scoring system. Secondary 
endpoints were clinician-reported outcomes of RTOG subjective xerostomia grade 2 
or more, measured saliva flow, and quality of life. I submitted my initial trial proposal 
to CRUK who requested a full application. At that stage I started to collaborate with 
The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU). 
Together with a trial manager and statistician we developed the protocol and were 
awarded full funding in 2003. 
  
At the start of PARSPORT, detailed procedures for the implementation of IMRT had 
not yet been established in the UK and, although some centres in the UK had started 
IMRT programs (Clark, Mubata et al. 2002) (James, Scrase et al. 2004), most centres 
joining the study had not yet implemented head and neck IMRT. In addition, only 
some early recommendations in general implementation had been published in the 
USA (Ezzell, Galvin et al. 2003; Galvin, Ezzell et al. 2004), as well as some initial 
quality assurance recommendations for IMRT in the head and neck (Marcie, Aletti et 
al. 2003; Zefkili, Tomsej et al. 2004). Prior to opening the trial, I had to form a Trial 
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Management Group (TMG) consisting of the principal investigator from each centre 
as well as physicists, radiographers, statisticians and trial managers. The TMG agreed 
a trial protocol which included the TVD guidelines and QA requirements. A rigorous 
QA programme to cover all aspects of the patient pathway, from target volume 
definition to verification, was designed for participating centres to ensure parity of 
treatment planning, pre-treatment verification and delivery across the different 
institutions. The program also served to give the centres a structure on which to base 
their IMRT protocol and provided guidance and support for clinical implementation. 
 
As many centres were starting IMRT, there was also an element of teaching required 
in the set-up process and this was provided at the trial launch day, and by running 
regular IMRT courses at RMH. A dosimetry audit was carried out after the centres 
had joined the trial and patients had been entered.  
 
The main results of the dosimetry audit (paper 6) were that while each centre was 
using different equipment (planning systems and linear accelerators) to deliver IMRT, 
that they could all reach agreement as to a standard process to deliver the trial 
treatments. Furthermore the adoption of the outlining guidelines presented in paper 4 
was acceptable, and that the medical physicists in each department were able to 
produce treatment plans which fulfilled the criteria laid out in the trial protocol 
document. This observation would be confirmed a few years later when the trial 
outcome reports found that over 90% of treatment plans (91% conventional and 98% 
of IMRT plans) had been delivered within protocol. In total 10 UK centres completed 
the entire pre-trial QA process of which 2 had no prior experience of IMRT planning 
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or delivery. Since this piece of work was completed, there have been other trials of 
IMRT in head and neck cancer and other tumour types. The success of our experience 
has been used to set up a National Radiotherapy Trials QA group (RTTQA) and has 
developed an IMRT accreditation program for centres entering IMRT trials of breast 
and prostate cancer in the UK. Similar programs have also been implemented in 
Europe (EQUAL-ESTRO) and in the US (RTOG QA). It is now widely held that 
rigorous QA is an essential part of any trial where radiotherapy is an important 
component of the treatment.  
 
As well as the departmental processes and the treatment planning, an equally 
important aspect is that the delivery of IMRT on the linear accelerator is accurate and 
that the radiation dose is reproducible in all participating cancer centres. This 
importance of this has recently been demonstrated in a trial carried out by the TROG 
group (Peters, O'Sullivan et al. 2010). They performed a trial of chemoradiation with 
the addition of a hypoxic cell sensitizer in head and neck cancer. The primary 
endpoint of the trial was not met, but in an interesting retrospective analysis they 
looked at the outcomes of patients whose radiotherapy had been given according to 
the protocol, and compared that to patients who had minor or major deviations from 
the protocol. It was seen that major deviations to the protocol led to a reduction in 
tumour control and survival of 10-20%.  
 
In paper 6, I present the outcome of a dosimetry audit which we performed for all the 
centres that entered patients into the PARSPORT trial. This consisted of treatment 
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planning system tests, fluence verification films, combined field films and dose point 
measurements inside a head and neck phantom. 
 
The results of this study were that, from the 6 participating centres, the standard 
deviation of the dose measurements was within ±2.5%. As a consequence of this 
work, a national recommendation was made that a 3% tolerance was appropriate for 
dose points within the PTV for multi-centre IMRT trials. 
 
2.7 PARSPORT trial results (paper 7) 
I undertook a randomised controlled trial between Jan 21, 2003, and Dec 7, 2007, that 
compared conventional radiotherapy (control) with parotid-sparing IMRT. We 
randomly assigned patients with histologically confirmed pharyngeal squamous cell 
carcinoma (T1–4, N0–3, M0) at six UK radiotherapy centres between the two 
radiotherapy techniques (1:1 ratio). A dose of 60 or 65 Gy was prescribed in 30 daily 
fractions given Monday to Friday to the primary tumour site and involved lymph 
nodes and 54Gy to elective lymph node regions. Randomisation was by computer-
generated permuted blocks and was stratified by centre and tumour site. Our primary 
endpoint was the proportion of patients with grade 2 or worse xerostomia at 12 
months, as assessed by the LENT SOMA scale. Analyses were done on an intention-
to-treat basis, with all patients who had assessments included. Long-term follow-up 
of patients is ongoing. This study was registered with the International Standard 
Randomised Controlled Trial register, number ISRCTN48243537. 
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The Consort diagram (paper 7 Figure 1) shows the outcomes of patients entered into 
the trial. Table 1 shows the patient characteristics. Again, the trial represents a typical 
head and neck population, being typically male aged just under 60 years. The 
majority of patients had oropharynx tumours and most had stage III-IV disease. 
Approximately 40% of patients had induction chemotherapy which was well balanced 
between the arms. The mean contralateral parotid gland dose was 25.4 (range 23.2-
28) Gy for IMRT patients and 61 (range 54.6-63.8) Gy in conventional radiotherapy 
patients. Corresponding ipsilateral parotid gland doses were 47.6 (range 39.9-54.5) 
Gy and 61 (range 57.0-64.4) Gy respectively (paper 7, Table 1). 
 
Figures 2a and 2b in the paper show the proportion of patients with high grade (≥G2) 
xerostomia using both the LENT SOMA and the RTOG scoring systems. They both 
show a similar pattern, with xerostomia rates in the conventional arm of 70.8-86.2% 
(LENT SOMA Conventional arm) compared to recovery in the IMRT arm: 38.5% at 
12 months, 31.4% at 18 months, and 29% at 24 months. The RTOG data show a 
similar pattern. The RTOG definition of G2 xerostomia is slightly different being 
“partial or persistent dryness of the mouth with little or no response on stimulation” 
compared to the LENT SOM definition of “complete dryness of the mouth”. 
  
Other acute side effects of radiotherapy were not reduced by IMRT (paper 7, table 2). 
Unexpectedly, acute fatigue was more common in the IMRT patients. The cause for 
this remains unknown, but subsequent research suggests that the dose to the brain was 
higher with IMRT than conventional radiotherapy, and that this might be the 
underlying cause. 
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The patient-reported xerostomia was supported by the saliva collection results which 
showed that patients who had received IMRT had a higher chance of producing 
measurable quantities of saliva compared to conventional radiotherapy patients. 
 
The EORTC QLQ-C30 instrument was used to measure global quality of life. At 24 
months after radiotherapy, there was an 11.1 point score difference between IMRT 
patients and those treated with conventional radiotherapy. This represents a clinically 
significant difference in global QoL for patients who received IMRT. 
 
The PARSPORT trial showed a significant reduction of radiation-induced xerostomia 
for patients treated with IMRT compared with conventional radiotherapy by use of 
both LENT SOM and RTOG scales. Furthermore, the trial showed recovery of saliva 
flow by quantitative measurements, and improvements on QoL measures associated 
with xerostomia. To my knowledge, this trial is the first to show that parotid-sparing 
IMRT reduces xerostomia in head and neck squamous cell carcinoma. A consistently 
higher QLQ-C30 global and QLQ-HN35 dry mouth score was reported in patients 
who received IMRT; between group differences at 24 months were clinically but not 
statistically significant. Xerostomia questionnaire results showed changes in favour of 
IMRT in all eight questions but these differences were not large enough to reach 
statistical significance, probably because of the small number of patients that 
completed this questionnaire. Although an association between measurable saliva 
flow and presence of grade 2 or worse xerostomia was recorded, there was not perfect 
concordance. We postulate that this could be because of differences in patient 
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perception of the xerostomia symptom or because of other factors such as 
submandibular gland or oral cavity dose or co-morbidity. Detailed analyses of the 
distribution of dose to the salivary tissue including parotid glands and other minor 
salivary glands, and its correlation with clinical outcomes are ongoing. Initial results 
suggest that there is no correlation between submandibular gland dose and 
xerostomia. 
 
A limitation of our trial was that it was not possible to mask the treatments from 
patients or clinicians because of differences in treatment delivery. Assessments were 
therefore unblinded. However, results that relate to multiple secondary endpoints 
support the primary analysis and the size of the observed effect is unlikely to be due 
entirely to assessment or reporting bias. After our trial was designed, several small 
non-randomised studies and one case-control study (Fang, Tsai et al. 2007) of 
parotid-sparing IMRT have been published with a range of endpoints including saliva 
flow rate, patient-reported symptoms, and QoL (see summary table 2.4). These 
studies reported apparent improvements for IMRT over conventional radiotherapy. 
 
Two small single-institution randomised phase 3 trials of IMRT in nasopharyngeal 
cancer have also reported benefits of IMRT over conventional radiotherapy. Pow and 
colleagues (Pow, Kwong et al. 2006) reported an increase in stimulated whole saliva 
flow rate in patients receiving IMRT in a randomised trial of 51 patients with early-
stage nasopharynx cancer. QoL was assessed with EORTC QLQ-C30, QLQ-HN35, 
and the SF36 health survey and although QoL scores for some domains were better 
for IMRT patients, no improvements in patient-reported dry mouth symptoms on the 
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HN35 questionnaire were noted. Kam and colleagues (Kam, Leung et al. 2007) 
reported a reduction in observer-rated severe xerostomia (RTOG grade 2 or worse) 
with IMRT (39% vs. 82%; p=0.001) in 60 patients with early-stage nasopharyngeal 
cancer. The results of the PARSPORT trial are thus likely to be generalisable to all 
head and neck tumours for which conventional radiotherapy is used. 
 
In our study, fewer cases of acute dermatitis were recorded in patients treated with 
IMRT than in those treated with conventional radiotherapy, although differences were 
not statistically significant at the 1% level, probably because of reduced dose to skin. 
The proportions of patients that reported grade 2 or worse acute xerostomia and grade 
2 or worse salivary gland changes also showed reductions, albeit not statistically 
significant. Late xerostomia side effects thus accord with acute side effects; this 
suggests that late radiation-induced xerostomia is a consequential effect. 
 
We did not attempt to spare the submandibular or mucosal minor salivary glands 
within the planning target volume in our trial. It is possible that further reductions in 
severe xerostomia can be achieved by sparing these tissues, but this might risk 
underdosing crucial target tissues. Unexpectedly, acute fatigue was greater in patients 
treated with IMRT, which could be due to the greater radiation dose to non-tumour 
tissues. In an unplanned dosimetry review in a subset of patients, mean radiation 
doses to the posterior fossa were 20–30 Gy in the patients treated with IMRT 
compared with about 6 Gy in patients treated with conventional radiotherapy, which 
could account for the recorded difference in acute radiation induced fatigue. Late 
fatigue data were not collected because lethargy is not a recognised long-term side-
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effect of radiotherapy. There was no significant association between the giving of 
neoadjuvant chemotherapy and either acute fatigue or xerostomia. The addition of 
concurrent chemotherapy to altered fractionation radiotherapy remains experimental 
and was not used in our study. 
 
Further research is needed to establish the effect of concurrent chemotherapy on 
xerostomia. Apart from salivary gland changes and radiation-induced xerostomia, 
other late side-effects of conventional radiotherapy were not altered by IMRT. 
 
Our trial was too small to detect small differences in, or conclude non-inferiority of, 
locoregional progression free survival (PFS) or overall survival (OS). Although 
patients continue to be followed up for long-term survival, to show non-inferiority in 
overall survival to no more than 5% at 2 years (80% power, one sided 5% 
significance) would need a randomised controlled trial of more than 900 patients. In 
this, and other, head and neck IMRT studies most tumour recurrences happen within 
the high-dose volume. Recurrences have not been noted in the spared parotid tissue in 
patients treated with IMRT or surgery, suggesting that a large study to show non-
inferiority in this tumour type is probably both impractical and inappropriate. Our 
trial has shown a clinically and statistically significant reduction in xerostomia, 
improved salivary flow, and improved QoL, and thus strongly supports a role for 
IMRT in HNSCC. 
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In the next chapter I will move away from the question of reducing normal tissue 
radiation toxicity and present data on the use of IMRT to increase radiation dose to 
head and neck tumours in an attempt to improve local tumour control. 
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Table 2.4 Summary table of published literature on parotid-sparing IMRT for head and neck cancer 
 
Study 
Mean Parotid Dose in Gray (Gy) Benefit from IMRT 
IMRT RT Xerostomi
a 
Functiona
l QoL Conventional Conformal 
Pow (Pow, Kwong et al. 2006) 
Mean (SD; Range) 
Ipsilateral         42Gy (4.7; 31.3-51.2) 
Contralateral    41.3Gy (5.4; 33.1-51.8) n.a - - Yes No 
Vergeer (Vergeer, Doornaert 
et al. 2009) 
Mean (SD) 
Ipsilateral         28.7Gy (11.9) 
Contralateral    23.3Gy (11.2) 
Bilateral  
43.0 Gy - Yes Yes Yes 
Jabbari (Jabbari, Kim et al. 
2005) 
Mean (Range) 
Ipsilateral         50Gy (38.7-67.8)  
Contralateral    21.8Gy (14-35.5) 
Bilateral 
 55.0 Gy - Yes* - Yes 
Fang (Fang, Tsai et al. 2007)  n.a n.a n.a - Yes Yes 
Fang (Fang, Chien et al. 2008) 
Mean (Range) 
Right                47.64Gy (23.42-63.55) 
Left                  46.84Gy (21.44-64.37) - 
Bilateral  
60.0 Gy - No No 
Graff (Graff, Lapeyre et al. 
2007) 
Mean 
Bilateral          33.7Gy 
Mean dose <30Gy: 
     For one or both parotids in 63.5% of  patients 
     For both parotids in 23.8% of  patients 
Mean dose <26Gy: 
     For one or both parotids in 34.9% of  patients 
n.a - - Yes No 
McMillan (McMillan, Pow et 
al. 2006) 
Mean (Range) 
Right                 38.4Gy (29.6-46.1) 
Left                   40.4Gy (29.7 – 53.4) - - - - - 
Scrimger (Scrimger, Kanji et 
al. 2007) 
Mean (SD) 
Total Parotid Volume              27.1Gy (16.5) 
Spared Parotid Volume           18.4Gy (10.5) - - - - - 
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Lin (Lin, Kim et al. 2003) n.a - - - - - 
Parliament (Parliament, 
Scrimger et al. 2004) 
Mean (Range) 
Right Spared Parotid volume  22.8Gy (17.8 – 27.8) 
Left Spared Parotid volume    20.9Gy (17.9 – 24) 
Total Parotid Volume             30.0Gy (26.9 – 33.1) 
- - - - - 
Nutting 
[2011] 
Mean 
Ipsilateral         47.6Gy (range39.9-54.5 ) 
Contralateral    25.4Gy (range 23.2-28) 
Ipsilateral       
60Gy 
Contralateral  
60Gy 
- Yes - n.a 
 
SD Standard deviation   
RT Radiotherapy 
QoL Quality of Life 
IMRT Intensity Modulated Radiotherapy 
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3.1 Introduction 
This chapter focuses on three papers (papers 8-10) that aim to explore the potential of 
IMRT to deliver higher radiation doses to larynx and hypopharynx tumours. Paper 8 
is a theoretical treatment planning exercise and then papers 9 and 10 present the 
results of a clinical trial in patients suggesting that improvements in tumour control 
may be observed. The chapter concludes with a summary of a randomised trial which 
is currently recruiting patients in the UK. The chapter highlights the difficulty of 
conducting Phase I trials in radiotherapy and shows how I progressed the ideas 
through preclinical evaluation, through to Phase I, and then into a Phase III trial. 
 
Classical radiobiological teaching holds that increases in local tumour control can be 
anticipated with increasing radiation dose delivered to a tumour (Fu, Pajak et al. 
2000), and that this may translate into improvements in overall survival.  Squamous 
cell carcinoma of the head and neck has a high alpha/beta ratio and so this approach is 
anticipated to be particularly effective.  
 
Radical chemoradiation or surgery (laryngectomy/pharyngo-laryngectomy) with or 
without adjuvant radiation/chemoradiation has traditionally been the main treatment 
options for locally advanced tumours of the larynx and hypopharynx. Concomitant 
cisplatin chemoradiotherapy can achieve locoregional failure–free rates of 60–65% at 
2 years, with a laryngeal preservation rate of 35– 65% The Department of Veterans 
Affairs Laryngeal Cancer Study Group (1991); (Lefebvre, Chevalier et al. 1996; 
Forastiere, Goepfert et al. 2003). These treatment modalities offer similar overall 
survival rates when compared with surgery and have demonstrated improved 
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locoregional control and laryngeal preservation rates over the last 30 years (Marcial, 
Pajak et al. 1987; Lee, Cosmatos et al. 1995). This is particularly important in the 
maintenance of normal function, especially breathing and swallowing. 
 
A meta-analysis confirmed improved locoregional control and overall survival when 
altered, as opposed to standard, fractionation regimens were delivered (Bourhis, 
Overgaard et al. 2006). Unfortunately, combining concomitant chemotherapy with 
altered fractionation using conventional radiotherapy techniques can cause severe 
normal tissue toxicities and consequential morbidity (Maciejewski, Skladowski et al. 
1996; Jackson, Weir et al. 1997).  
 
IMRT delivers radiation more conformally and reduces the volume of normal tissue 
in the high-dose volume. Paper 8 aimed to test whether IMRT would produce a better 
dose distribution and allow dose escalation by modest hypofractionation in patients 
with tumours of the larynx and hypopharynx. 
 
3.2 Application of the IMRT technique to locally advanced larynx and 
hypopharynx cancers (paper 8) 
External beam radiotherapy for advanced cancer of the larynx and hypopharynx 
represents a difficult challenge for treatment planning because the PTV, which 
includes the larynx and bilateral cervical lymph nodes, is wrapped around the spinal 
cord (SC). 
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Typically in the UK, with conventional radiotherapy, lateral-opposed photon portals 
are used to treat the PTV up to cord tolerance and then reduced photon fields are 
matched to high-energy electrons bilaterally to treat the posterior cervical lymph 
nodes (Perez and Brady 1987; Dobbs, Barrett et al. 1999). This produces a concave 
dose distribution surrounding the SC, but there are areas of potential under dose in the 
photon–electron match line that may account for a proportion of patients who relapse 
in the cervical nodes.  
 
A radiation dose of 65–70 Gy is required to eradicate macroscopic tumour in the 
larynx and involved lymph nodes, and 50 Gy elective irradiation to the cervical 
lymph nodes (Fletcher 1972). These doses are in excess of SC tolerance (absolute 
maximum of 48 Gy in 2 Gy fractions), and without careful treatment planning the 
patient is at risk of radiation-induced myelopathy due to the proximity of the target 
volume to the SC. 
 
In the treatment of carcinoma of the larynx and hypopharynx, IMRT may offer the 
potential to improve target coverage and increase the sparing of the organs at risk 
(OAR). The primary aim of the study in paper 8 was to investigate whether IMRT 
could improve coverage of the larynx and nodal PTVs compared to conventional 
techniques whilst maintaining SC sparing. The second aim of the study was to 
investigate if dose escalation was technically possible within SC tolerance. A 
planning study was performed using the principles outlined in Chapter 2. 
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The main findings of paper 8 were that IMRT plans had better dose distributions than 
conventional plans (see paper 8 figures 2-7 and tables 2-4). Figure 3.1 shows a typical 
patient dose volume histogram and demonstrates the increase in minimum dose 
delivered to PTV 1 and 2 and also the reduced dose to the spinal cord with IMRT. 
The reduction in spinal cord dose was such that dose escalation to greater than 67 Gy 
was possible within spinal cord tolerance. Target dose homogeneity was improved 
with IMRT plans. 
 
 
 
 
Figure 3.1 A dose-volume histogram showing data for a conventional and IMRT plan 
for a typical patient. The CRT plan data are shown as dotted lines and the IMRT is in 
solid lines. The IMRT data show a significant improvement in target coverage and 
dose inhomogeneity as well as improved cord sparing. 
 
 
3.3. Development of a clinical dose escalation trial 
The goals of radiotherapy for locally advanced (T3-4, N+) carcinoma of the larynx 
and hypopharynx are local control, survival and quality of life—specifically 
voice/larynx preservation. For T3N0 cases, the local control and survival rates with 
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radiotherapy alone are 50–60 and 60–70%, respectively. Two-thirds of patients will 
survive with a functional larynx (The Department of Veteran Affairs Laryngeal 
Cancer Study Group 1992). Other larynx-preserving approaches include the use of 
induction and/or concomitant chemoradiation (The Department of Veteran Affairs 
Laryngeal Cancer Study Group 1992; Lefebvre, Chevalier et al. 1996), and 
radiotherapy dose escalation. Dose escalation strategies have employed accelerated, 
hyperfractionated, and continuous, hyperfractionated accelerated radiotherapy 
(CHART) schedules which show an increase in local control and support the 
hypothesis of a steep dose–response relationship for squamous cell carcinoma of the 
head and neck (Fu, Pajak et al. 2000). Induction chemotherapy schedules have not 
been shown to have a significant effect on improving overall survival, although 
cisplatin doublets may increase the response rate and increase local tumour control. 
 
Concomitant chemo-radiation strategies are now the standard of care in locally 
advanced head and neck cancer. In a large meta-analysis, concomitant chemo-
radiation had a 9% advantage over radiotherapy alone (Pignon, Bourhis et al. 2000). 
Such strategies may carry increased normal tissue toxicity, and there is uncertainty as 
to the net effect on the therapeutic ratio (Henk 1997). 
 
3.3 Design of a dose escalation trial (paper 9) 
Putting all the above evidence together, I designed an IMRT schedule which 
combined induction chemotherapy and concomitant chemo-IMRT using a moderately 
accelerated fractionation scheme. I hoped that this would offer the benefits of 
induction and concomitant chemoradiation and at the same time that the accelerated 
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IMRT would be more tolerable for patients than acceleration delivered by 
conventional radiotherapy techniques. The dose and fractionation technique is shown 
in Table 3.1.  
 
 PTV 1 PTV 2 
Dose level 1 63.0Gy 28# (2.25Gy) 
BED10Gy 66.6, BED3Gy 110.3 
Log cell kill 10.12 
 
52Gy 28# 
(1.85Gy) 
N/A 
Dose level 2 67.2Gy 28# (2.4Gy) 
BED10Gy 72.8, BED3Gy 121.0 
Log cell kill 11.06 
56Gy 28# 
(2.0Gy) 
N/A 
Conventional  
70Gy 35# 
70Gy 35# (2Gy) 
BED10Gy 74.1, BED3Gy 116.67 
Log cell kill 10.26 
 
50 Gy 25# 
(2Gy) 
N/A 
 
Table 3.1 Dose schedules used in the dose escalation trial 
 
The proposed radiotherapy technique had several potential risks. First, I was 
proposing an accelerated radiotherapy schedule with concurrent chemotherapy. As 
detailed above, other studies that used more accelerated techniques had demonstrated 
severe acute toxicity with this approach. Second, I had proposed delivering greater 
than 2 Gy per fraction (2.2 Gy in the first dose level (DL1), and 2.4 Gy in the second 
dose level (DL2)). Within PTV 1 were some normal tissue structures with a low 
alpha: beta ratio which may have increased risk of normal tissue injury when 
delivering greater than 2 Gy per fraction. I was particularly concerned about the risk 
of laryngeal cartilage necrosis and also cervical oesophagus strictures. 
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These safety concerns led me to the decision to evaluate this technique using a phase 
I trial design. Phase I trials have traditionally been used to assess the safety of new 
drugs in patients with incurable recurrent cancer for whom there are very few 
treatment options. Typically, increasing doses of the drug under evaluation are 
administered to small numbers of patients over a short period of time until acute dose-
limiting toxicity (DLT) is reached. Once DLT is established, then the previous non-
toxic dose level is usually taken forwards into Phase II trial testing (Harrington, 
Billingham et al. 2011). 
 
In radiation oncology, phase I trials are problematic.  First, DLT for most radiation 
techniques are late effects which may take months or years to appear and may be 
progressive over time. Second, we were proposing to evaluate this dose escalation 
strategy in previously untreated patients who had a reasonably good chance of long-
term cure, even with standard dose radiation. 
 
With this in mind, I designed a quite conservative dose escalation strategy and wrote 
into the protocol stringent safety stopping rules based on ≥G3 toxicity (see paper 9). 
The trial design was to enrol 15 patients for each dose level initially, expanding to 30 
if a late toxicity was reported. The main expected toxicities were late, specifically 
laryngeal cartilage necrosis, and oesophageal stricture. 
 
Phase I stopping rules were, that if 0/15 had ≥G3 toxicity (defined as a radiotherapy 
toxicity requiring surgery to correct it) then ≥20% risk of ≥G3 late complications was 
excluded with 95% power. If 1-2 of 15 developed ≥G3 toxicity then that cohort 
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should be expanded to 30 patients to improve statistical power. If 1 or 2 of 30 had 
≥G3 toxicity then the incidence of ≥G3 toxicity was estimated at 0-17% or 0-22%, 
respectively. If >2/30 had ≥G3 toxicity then the predicted grade ≥G3 toxicity would 
be 2-27% with 95% power which would be deemed too unsafe to continue and the 
recruitment to the trial would be stopped. 
 
3.4 Clinical Results of the dose escalation trial (Paper 10) 
Overall, 60 patients were recruited to the study. The patient characteristics are given 
below. 
 DL1 63Gy/ 28F DL2 67.2Gy/28F 
No of patients 
 
29 31 
Median follow up months 
(range) 
49.0  
(35.7- 78.3)  
35.7  
(17.7-62.8) 
Age (years) 
Mean  
 
58 (35-80) 
 
63 (43-85) 
Sex 
Male 
Female 
 
23 (79.3) 
6 (20.7) 
 
24 (77.4) 
7 (22.6) 
Performance status 
0 
1 
 
24 (82.8) 
5 (17.2) 
 
30 (96.8) 
1 (3.2) 
Primary Tumour Site 
Larynx 
Hypopharynx 
 
17 (58.6) 
12 (41.4) 
 
16 (51.6) 
15 (48.4) 
TNM Stage 
I 
II 
III 
IVA 
IVB 
 
1 (3.4) 
1 (3.4) 
12 (41.3) 
13 (44.8) 
2 (6.9) 
 
0 
0 
16 (51.6) 
15 (48.3) 
0 
Neoadjuvant chemotherapy 
Yes  
No  
 
29 (100) 
0  
 
29 (93.5) 
2 (6.5) 
Concomitant chemotherapy 
given 
29 (100) 30 (97) 
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Table 3.2 Patient Characteristics; DL = Dose level; F = fractions 
 
The trial participants were typical of the head and neck population being 
predominantly male aged around 60. The balance of larynx and hypopharynx tumours 
was, by chance, similar which was fortunate because the prognosis stage for stage is 
not the same, being worse for hypopharynx cancers. Ninety-three percent of cases 
were stage III or IV, although two patients with earlier stage hypopharynx cancers 
were included in DL1.  
  
Acute toxicity is presented in Figure 1 and 2 and Table 3 of paper 9 and updated in 
Table 2 of paper 10. Late radiotherapy toxicity is presented in Table 3.3 below.  
 
Overall 3 patients had ≥G3 late toxicity. In the first 15 patients in DL1, no patient had 
toxicity. On that basis we proceeded to DL2.  In dose level 2, two toxicities were 
observed. One oesophageal stricture which was treated conservatively and one 
stricture which failed dilatation and required laryngopharyngectomy (no tumour 
found on pathology). While the data on DL2 were maturing, we returned to DL1 and 
treated another 15 cases to that dose. This was done to increase the statistical power 
of the DL1 patient group. One of those second 15 cases developed a benign stricture 
and required dilatation. Overall the G3 toxicity rate was 5% for DL1 and 8% for DL2.  
(Table 3.3)  
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 Number of patients by late toxicity grade at 1 year 
(%) 
Dose Level 1 
n=29 
Dose Level 2 
n=31 
0 1 2 3 4 0 1 2 3 4 
Skin 16 
(76) 
4 
(19) 
1 
(5) 
0 0 21 
(88) 
3 
(12) 
0 0 0 
Mucosa 12 
(57) 
9 
(43) 
0 0 0 17 
(71) 
7 
(30) 
0 0 0 
Subcutaneous Tissue 18 
(86) 
3 
(14) 
0 0 0 15 
(63) 
7 
(30) 
2 
 (7) 
0 0 
Larynx 9 
(43) 
7 
(33) 
5 
(24) 
0 0 6 
(25) 
14 
(58) 
4 
(17) 
0 0 
Oesophagus 15 
(71) 
5 
(25) 
0 1  
(5) 
0 
 
15 
(60) 
7 
(29) 
0 1 
(4) 
1 (4) 
Salivary Gland 10 
(48) 
9 
(43) 
2  
(9) 
0 0 9 
(38) 
13 
(54) 
2 
(8) 
0 0 
Spinal Cord 21 
(100) 
0 0 0 0 24 
(100
) 
0 0 0 0 
 
 
Table 3.3 Type and Frequency of Late Radiotherapy Adverse Effects (N=60) 
 
Treatment outcome at 2 years is presented in Table 3.4. The locoregional control rate 
appeared higher in DL2 than DL1 (85.9% vs. 70.8%), as did the laryngeal preservation 
rate (96.4% vs. 88.7%). Kaplan Meier curves for local control and survival are 
presented in paper 10. 
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 DL1 
n=29 
%- (95% CI) 
DL2 
n=31 
%- (95% CI) 
Median Follow Up 
 
51.2 months 
range 12.1-77.3 
36.2 months  
range 4.2-63.3 
Local control rates  
 
70.8 
(49.7-84.3) 
85.9 
(66.7-94.5) 
Locoregional control rates 
 
67.6 
(46.7-81.7) 
81.8 
(61.6-92.1) 
Loco-regional progression free 
survival 
64.2 
(43.5-78.9) 
78.4 
(58.1-89.7) 
Disease free survival 61.5 
(58.8-89.9) 
78.4 
(58.1-89.7) 
Larynx preservation rate 
 
88.7 
(68.5-96.3) 
96.4 
(77.2-99.5) 
Overall survival 72.4 
(52.3-85.1) 
74.2 
(55.0-86.2) 
 
Table 3.4: Treatment outcomes at 2 years   
 
3.5 Design of ART DECO, a dose escalation trial 
In some studies, locally advanced head and neck cancer has benefited from altered 
radiotherapy fractionation regimens (pure acceleration or altered fractionation with a 
higher total dose) (Overgaard, Hansen et al. 2003; Overgaard, Mohanti et al. 2010). 
The RTOG 9003 study concluded that hyperfractionation or accelerated fractionation 
with concomitant boost provided significantly better locoregional control when 
compared with conventional fractionation (54.5% vs. 46.0% at 2 years) (Fu, Pajak et 
al. 2000). Accelerated radiotherapy, compared with a conventional treatment of 7 
weeks, can achieve maximum shortening in treatment time of 2 weeks, with the high 
grade mucositis being the DLT and any further acceleration requiring a reduction of 
dose. Further dose escalation schedules with conformal radiotherapy techniques had 
been unsuccessful because of unacceptable acute and or late toxicity. Maciejewski et 
al. (1996) compared a 70 Gy in 35 daily fractions over 7 days per week fractionation 
Chapter 3 
93 
 
schedule versus a 5 days per week schedule and found an unacceptably high 
incidence of severe acute reactions and consequential late effects in the accelerated 
arm. Jackson et al. (1997) randomized 66 Gy in 33 daily fractions once daily vs. twice 
daily. The trial was discontinued early because of an increase in Grade 4 toxicity in 
the accelerated arm. Phase III trials have demonstrated a lower incidence of patient-
reported toxicities with IMRT when compared with conformal radiotherapy 
techniques in the treatment of oropharyngeal (Nutting 2009) and nasopharyngeal 
cancers (Pow, Kwong et al. 2006; Kam, Leung et al. 2007). However, dose escalation 
IMRT studies in the treatment of locally advanced head and neck cancers are sparse.  
 
In my sequential cohort Phase I/II study, both accelerated hypofractionated 
radiotherapy regimens with induction and concomitant chemotherapy were found to 
be deliverable without treatment breaks. Dose Level 2 confirmed that dose escalation 
is feasible with an increase in acute toxicities, but with similar late radiation toxicity 
at two years. The Phase I goals of the study were therefore met.  
 
During our study, Madani et al. reported the results of their Phase I dose escalation 
trial (Madani, Duthoy et al. 2007). They assessed the feasibility of positron emission 
tomography–guided focal dose escalation using IMRT. Patients received 25 Gy in 10 
daily fractions to a sub-volume within the GTV. Standard 2.16 Gy per fraction was 
applied to the remainder of the volume and then to the combined target volumes for 
the remaining 22 fractions. There were two cases of DLTs (Grade 4 dermatitis and 
Grade 4 dysphagia) out of the 18 reported cases. The second dose level delivered 30 
Gy in 10 fractions to the positron emission tomography–defined volume within the 
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GTV. The study was stopped after a treatment-related death (sepsis and renal failure) 
at the second dose level.  
 
This gave me grave concerns about proceeding further with dose escalation. The trial 
by Madani had escalated radiation doses by about 20% compared to our trial where 
an estimated 10% dose escalation had been achieved. This was obviously a very 
disturbing observation and I felt that increasing another dose level with our technique 
may run into severe acute toxicity problems. At the same time, we were analysing the 
locoregional control data and I realised that the DL2 results suggested an 
improvement in local control and larynx preservation rate without increasing long-
term toxicities.  
 
Lee et al. (2007) reported a retrospective review of laryngeal and hypopharyngeal 
cancers treated with concurrent chemotherapy and IMRT. All patients experienced 
RTOG ≥G2 pharyngitis during treatment. Two-year percutaneous endoscopic 
gastrostomy dependence rates were 31% and 15% for hypopharyngeal and laryngeal 
cancers, respectively. Percutaneous endoscopic gastrostomy dependence was related 
to pharyngeal stricture, high-grade dysphagia, or laryngeal aspiration (Lee, O'Meara 
et al. 2007). Our study defined very conservative stopping rules: the incidence of 
high-grade dysphagia at 1 year was 6% in DL2, whereas incidences reported in the 
literature are around 30% (Jeremic, Shibamoto et al. 2000; Staar, Rudat et al. 2001; 
Lee, O'Meara et al. 2007). The mean dose delivered to the inferior constrictor 
muscles in DL2 was 68.1 Gy (range, 65.5–69.3 Gy). We observed no cases of 
laryngeal cartilage necrosis or laryngectomy for a dysfunctional larynx. Patients with 
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successful organ preservation also maintained acceptable function. In our study, no 
formal functional outcome measures of speech and swallow were undertaken. These 
will be included in our subsequent studies alongside quality of life parameters. 
 
The RTOG has described age, tumour stage, primary site (larynx/ hypopharynx), and 
neck dissection after chemoradiation as factors associated with severe late toxicity 
after concomitant chemoradiation for locally advanced squamous cell cancer of the 
head and neck (Machtay, Moughan et al. 2008). They also demonstrated that the peak 
incidence of severe toxicity occurs at 3 years after treatment. In our study there has 
been no increase in incidence of high-grade (Grade ≥3) radiation-related late 
toxicities at 2 to 3 years compared with the reports at 1 year. Within the limitations of 
this small study, improved treatment outcomes were reported in DL2. Local control 
rates at 2 years in the two cohorts were 70.8% and 85.9% in DL1 and DL2, 
respectively, with larynx preservation rates at 2 years of 88.7% and 96.4%. The 
difference between these two outcome measures is explained by the patients either 
being unfit for salvage surgery or that the disease was deemed inoperable. 
Locoregional control rates at 2 years for the two dose levels with a median follow-up 
of 24 months for DL1 and 21 months for DL2 were reported as 65% and 85%, 
respectively (Nutting, Miah et al. 2009). To emphasize, the study was too small to 
determine differences in locoregional control and survival, and the Phase I/II trial 
design was inappropriate to assess this outcome in detail. However, the potential 
difference in overall response rates and locoregional recurrences between the two 
cohorts could be due to increased radiobiological effectiveness of DL2. It has been 
suggested that DL1 represents an inferior radiobiological effective dose. However, 
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when we compare DL1 outcomes with those reported in the literature using 
conventional dose and fractionation, the locoregional control rates are similar at 60–
65% at 2 years for laryngeal cancers. With longer median follow-up of 51.2 months 
for DL1 and 36.2 months for DL2, an improvement in locoregional control is 
maintained.  
 
As a consequence of the improved locoregional control and larynx preservation rates 
and concerns about acute toxicity of further dose escalation, I decided to proceed to 
examine the DL2 schedule in a randomised controlled trial. The trial schema is 
presented below in Figure 3.2. ART DECO Phase III Trial Schema
Induction chemotherapy 
[Optional by centre]
C
O
N
S
E
N
T
Male or 
female 
patients aged 
18-70 with 
locally 
advanced 
squamous cell 
cancers of the 
larynx or 
hypopharynx 
requiring 
definitive 
treatment with 
chemo-
radiotherapy
Complete 
baseline 
Quality of 
Life 
Radiotherapy - Experimental Arm 
67.2Gy in 28 fractions to the involved 
site and nodal groups
56Gy in 28 fractions to nodal areas at 
risk of harbouring microscopic disease.
Radiotherapy - Conventional Arm 
65Gy in 30 fractions to involved site 
and nodal groups
54 Gy in 30 fractions to nodal areas at 
risk of harbouring microscopic disease.
Patients may receive a 
maximum of 3 (21 day) cycles 
of platinum based induction 
chemotherapy prior to 
radiotherapy
All patients will receive 
concomitant platinum 100mg/m2 
on day 1 & 29 of their RT schedule
R
Figure 3.2 ART DECO phase III trial schema 
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In this trial, which opened to recruitment in 2011, patients with locally advanced 
squamous cell carcinoma of the larynx or hypopharynx are randomised to receive 
either UK standard dose IMRT  (65 Gy in 30 fractions) or the DL2 schedule. Patients 
in both treatment arms will receive concomitant chemotherapy with cisplatin and can 
also receive induction chemotherapy at the investigator’s discretion. The trial is 
stratified by treatment centre and each centre will provide their own induction 
chemotherapy schedule such that different chemotherapy schedules will be balanced 
on both arms of the study by the randomisation process. The primary endpoint is to 
determine whether there is an improvement of locoregional failure–free rate at 2 years 
compared with standard-dose chemotherapy-IMRT. In conjunction with recently 
published consensus guidelines for laryngeal preservation studies, we will also 
evaluate laryngeal and oesophageal dysfunction and associated quality of life 
(Lefebvre and Ang 2009). At the time of writing approximately 20 patients have been 
randomised within this clinical trial. 
This Chapter has demonstrated the progression of medical scientific discovery 
through preclinical evaluation, to early phase trials, and then the design of a Phase III 
RCT in head and neck cancer patients. In the final chapter I will review some of the 
methodological ideas used in this thesis as well as the research and development 
infrastructure in the UK which led to this method of research. I will explore some of 
the ethical issues around the RCT design and suggest some future directions for 
research. 
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Conclusions and Future Directions 
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4.1 Introduction 
In this thesis I have explored the use of IMRT to reduce toxicity and improve tumour 
control rates for patients with head and neck cancer. Chapter 2 detailed the resolution 
of obstacles for local and then national implementation and evaluation of IMRT 
through a randomised controlled trial. This trial demonstrated a clinically and 
statistically significant benefit in reduction in xerostomia, the main long term side 
effect of head and neck radiotherapy. This trial provided proof-of-principle that 
IMRT could be used to reduce parotid gland radiation dose compared to conventional 
radiotherapy leading to reduced symptoms and improved quality of life, while 
maintaining tumour control rates. 
 
Currently a second randomised controlled trial called COSTAR (principal 
investigator Nutting) is recruiting patients in the UK. This trial aims to reduce 
radiation-induced hearing loss in patients who are being treated with adjuvant 
radiotherapy to the parotid following surgical resection of a malignant parotid 
tumour. The trial design is similar to the PARSPORT trial, and the endpoint of this 
trial is high frequency hearing loss measured by an audiogram one year after 
radiotherapy. The COSTAR trial is predicted to close in autumn 2012 and results 
should be available in late 2013. 
 
4.2 Methodological issues 
The randomised controlled trial methodology is widely accepted as being the gold 
standard for evaluation of a new health care intervention (Moher, Hopewell et al. 
2010). Evidence from RCTs is designated level II evidence – “evidence from at least 
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one properly designed RCT”. (National Health and Medical Research Council 
(Australia) 1998). This form of trial design helps reduce spurious causality and avoid 
bias or confounding factors. Results of RCTs may be combined to produce systematic 
reviews, the highest hierarchy of evidence-based medicine (Level I evidence (Oxford 
centre for evidence based medicine (2009)).  However, RCTs have their own 
limitations and risks (Black 1996; Sanson-Fisher, Bonevski et al. 2007). Among the 
most frequently cited scientific drawbacks are limitations of external validity, cost, 
time, and statistical problems. The validity of a RCT result for the general population 
may be affected by where the trial was performed, the characteristics of the patients 
entered into the trial, the outcome measures chosen and the completeness of data 
collection. Furthermore, the informed consent process has the potential to introduce a 
systematic bias by patient selection. RCTs are expensive to perform and may take 
many years to recruit and follow up patients to the chosen endpoint. RCTs are subject 
to both type I (false positive) and type II (false negative) errors. A typical trial design 
using p<0.05, will have a 1:20 chance of a type I error. Despite these drawbacks, 
global healthcare systems typically demand data from RCTs to decide on major 
changes in clinical practice, especially when assessing new high-cost technology. In 
the UK the Department of Health is responsible for developing and assessing 
evidence to inform development of medical technology for the benefit of patients and 
the public. The National Institute for Health and Clinical Excellence (NICE) develops 
evidence-based guidelines on the most effective way to diagnose, treat and prevent ill 
health. NICE generates Clinical Guidelines as well as performing Technology 
Appraisals. As part of the process of evaluation of a new intervention, NICE reviews 
evidence collated by the National Clinical Guideline Centre (NCGC) which 
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systematically reviews the evidence for that technology. Selection of relevant studies 
and assessing their quality are some of the most important tasks in this process (NICE 
guidelines manual 2009). The following quotation is taken from their manual: “Well-
conducted randomised controlled trials are more likely than non-randomised studies 
to produce similar comparison groups, and are therefore particularly suited to 
estimating the effects of interventions”. Therefore in the UK the RCT is critical for 
evaluation of health care technology for clinical implementation in the NHS. 
 
The design of both the PARSPORT and COSTAR trials has taken account of these 
factors. While the studies have been performed in the UK, both trials are relatively 
small. This was due to the large difference in outcome of the primary endpoint 
expected between the two arms of the trials. The trial participants were selected in 
that they had to fulfil all the inclusion and exclusion criteria of the trial. A small 
number of subjects were unable to join the trial because they refused to be 
randomised. This was usually because they had read that IMRT was “new” 
technology with possibly better outcomes than conventional radiotherapy. Other 
patients refused randomisation because of concerns about potential increased relapse 
rates in the untreated areas around the parotid gland which was a risk which was 
mentioned in the patient information sheet, and discussed during informed consent. 
One patient who refused randomisation travelled to the USA for IMRT. During the 
trial recruitment period, IMRT was not available in the UK outside of a trial. The 
choice of outcome measure in the PARSPORT trial (i.e. severe xerostomia (≥G2)) 
could be criticised, and if I had chosen a lower toxicity (≥grade 1 for example) then 
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the results of the trial may have been different, as G1 xerostomia is still reported by 
many patients treated with IMRT.  
 
Two studies published in the New England Journal of Medicine in 2000 suggested 
that RCTs and observational studies overall produced similar results (Benson and 
Hartz 2000; Concato, Shah et al. 2000). However a study in 2001 published in 
Journal of the American Medical Association (Ioannidis, Haidich et al. 2001) 
concluded that discrepancies beyond chance do occur, and differences in the 
estimated size of a difference between two treatments are seen between RCTs and 
observational studies. Such differences may influence healthcare providers’ decisions 
in funding new technologies. This raises an ethical dilemma with radiation oncology 
trials of normal tissue toxicity. Patients treated in the conventional arm of the 
PARSPORT trial suffered permanent dry mouth which will affect their QoL for their 
whole lifetime. This was predicted, but unproven, at the time of trial design (see 
below). As a consequence of the PARSPORT trial and associated research, IMRT has 
been accepted to be superior to conventional radiotherapy for reducing xerostomia 
and over 250,000 patients worldwide can potentially benefit from IMRT each year. 
 
4.3 Evidence base in 2002 compared to 2006/7 
In 2002 when the trial was conceived, there were two theoretical planning studies 
from University of Michigan that showed IMRT delivered a lower radiation dose to 
the parotid salivary tissue (Eisbruch, Marsh et al. 1998; Eisbruch, Ten Haken et al. 
1999). In addition there were early clinical reports from three US centres reporting 
reduction in xerostomia in head and neck IMRT patients (Ship, Eisbruch et al. 1997; 
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Kuppersmith, Greco et al. 1999; Chao, Low et al. 2000). One study had demonstrated 
maintenance of saliva flow following parotid sparing IMRT (D'Hondt, Eisbruch et al. 
1998). While promising, these studies were inadequate to make any conclusions 
about parotid gland sparing radiotherapy at that time. The reports were heterogeneous 
and contained small numbers of patients with no comparative groups. It is important 
at this point to also take into account the perceived disadvantages of parotid-sparing 
IMRT at that time. First, IMRT was still in its infancy, a new treatment available in a 
small number of specialist centres with no long term clinical outcome data. Second, 
the IMRT technique used multiple complex radiation beams which led to a less 
homogeneous radiation dose with significant variation in dose within the tumour 
compared to conventional radiotherapy. There were concerns as to whether this might 
lead to reduced tumour control rates if there were areas of low dose within the 
tumour, and specifically if parotid sparing IMRT would lead to geographical miss of 
tumour cells close to or within the parotid tissue (Dawson, Anzai et al. 2000). Third, 
the technique was time-consuming and therefore costly. As discussed in Chapter 2, 
there was an opportunity to test this technology in a RCT as there was clinical 
equipoise as to whether IMRT was overall beneficial to head and neck patients.  
 
It could be argued that a large multi-centre observational study in the UK would have 
been an alternative approach to the PARSPORT RCT, and may have come to the 
same conclusion without having to render patients xerostomic in the control arm. By 
contrast, in 2007 when the trial closed to recruitment, and 2009 when the results were 
first reported, the situation had changed. There were a number of larger Phase II 
single institution trials reporting consistently better recovery of saliva flow in patients 
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treated with parotid sparing IMRT (Parliament, Scrimger et al. 2004; McMillan, Pow 
et al. 2006; Fang, Tsai et al. 2007; Graff, Lapeyre et al. 2007; Scrimger, Kanji et al. 
2007). One case-control study (Jabbari, Kim et al. 2005) showed that IMRT reduced 
xerostomia rates and improved quality of life.   Two small randomised controlled 
studies in nasopharyngeal cancer from Asia, (Pow, Kwong et al. 2006; Kam, Leung et 
al. 2007) showed increases in saliva flow and reduction in xerostomia in IMRT 
patients compared to conventional radiotherapy. In respect of the PARSPORT trial it 
is clear that the position of clinical equipoise existed appropriately up until 2006-2007 
when the studies by Pow et al (2006) and Kam et al (2007) were published. This was 
contemporaneous with the closure of recruitment of PARSPORT. In retrospect, the 
period 2003-2007 was a window of opportunity for performing this trial and I do not 
think that it would have been possible to continue recruitment to PARSPORT beyond 
that time. 
 
The PARSPORT trial sample size was not large enough to statistically prove that the 
local tumour control rates were equivalent for both arms of the trial. In order to 
achieve this aim a much larger sample size would have been be required, which was 
not felt to be feasible. This remains a major criticism of the PARSPORT trial as while 
reduction in toxicity was demonstrated, equivalent local control was not statistically 
proven and so any overall gain in the therapeutic ratio remains uncertain (discussed 
on p77, chapter 2).  
 
In Chapter 3 I have presented data to show that dose escalation to larynx and 
hypopharynx cancers was theoretically possible with IMRT (paper 8). Papers 9 and 
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10 show clinical data from a non-randomised trial that suggests that this approach is 
safe, and also that it may lead to an improvement in local tumour control. The study 
design used in paper 9 and 10 is a sequential cohort design and the numbers of 
patients studied are too low to lead to any statistically valid conclusions about 
differences in outcomes between the two dose levels. However the ARTDECO trial is 
powered to measure a difference in local control rates between standard dose, and 
escalated dose IMRT. 
 
The potential consequences of irradiation of more tissue to low dose with IMRT 
remain uncertain. Parotid-sparing IMRT uses multiple beam directions and increases 
the radiation dose to some non-target structures such as the brain stem and 
cerebellum. This may well be the reason why increased acute fatigue was observed in 
the IMRT arm of the PARSPORT trial. This was an unexpected finding which is 
almost certainly a real observation (p<0.01), but had not been identified in any of the 
observational studies performed by other groups. The MD Anderson Cancer Centre 
reported an increase in acute normal tissue toxicity with IMRT and suggested that 
more careful avoidance of non-target structures should be performed (Rosenthal, 
Chambers et al. 2008). The low-dose irradiation of these and other tissues may be 
shown in the long term to be detrimental to patients, for example increased risk of 
cerebro-vascular disease or second malignancy. These toxicities would be expected to 
take years to manifest and are not part of the data collection of the RCT protocol.  
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4.4 Ethical issues 
At the time of the PARSPORT trial design, and throughout the recruitment period, 
there was clinical equipoise amongst the investigators regarding the risks and benefits 
of parotid-sparing IMRT based on the potential benefits and risks given above. As 
with many advances in medical science, the results, when viewed retrospectively 
looked very predictable especially when viewed in the context of the additional 
advances in knowledge that occurred during the recruitment period. However, I have 
often been asked “Surely it is self evident that reducing the radiation dose to the 
salivary glands will maintain saliva production – how could you ethically randomise 
patients?” Since the introduction of RCTs, there has been concern from medical 
professionals and lay people that this experimental design requires patients to 
potentially sacrifice their own best interests for the benefit of future patients, or the 
population as a whole  (Edwards, Lilford et al. 1998). Investigators have an obligation 
and a responsibility to ensure that patients do not come to any harm as a consequence 
of trial participation (World Medical Association Medical Ethics Committee 1999). 
This can be addressed on several levels. First, when possible, patients and carers 
should be involved at the stages of clinical trial design to ensure that what is being 
proposed in a trial is acceptable to potential participants. Second, before a trial starts, 
approval of an ethics committee must be sought. Third, informed consent must be 
obtained from competent patients (Williams 1994). These points are largely 
procedural and are legal requirements through Good Clinical Practice (GCP) (General 
Medical Council 2006 (updated 2009)). What is more difficult is the evaluation of 
developments which occur during trial recruitment after the initial protocol approval. 
Developments in the clinical science are part of the remit of a data monitoring 
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committee, but participating investigators may have their personal equipoise affected 
by peer pressure to continue a trial, personal investment of time and effort, or other 
reasons (Taylor and Kelner 1987; Tobias and Souhami 1993). In respect of the 
PARSPORT trial it is clear that the position of clinical equipoise existed 
appropriately up until 2006-2007 when the studies by Pow et al (2006) and Kam et al 
(2007) were published. This was contemporaneous with the closure of recruitment of 
PARSPORT. 
 
4.5 Future directions 
In the future I would like to see the development of studies aimed at improving 
swallowing following radiotherapy. The pharyngeal muscles are adversely affected 
by high dose radiotherapy and chemo-radiotherapy, with up to 50% of patients 
complaining of swallowing abnormalities after treatment (Roe 2011). The 
pathophysiology of this problem is poorly understood, but does seem to be related to 
the dose delivered to the pharyngeal muscles. Whether the problem is due to atrophy 
and fibrosis of the muscles themselves, or due to loss of neurological function is 
uncertain. Certainly it may be possible to achieve reductions in the extent of 
irradiation of these structures with IMRT and this could translate into improved 
swallowing function. In order to do this then I believe that better imaging of the 
extent of tumour may be required to give us more certainty in the definition of the 
target volume and thus the safety of reducing margins around GTV. This should be 
tested in a RCT with endpoints of swallowing and QoL. This thesis could be seen as a 
template for evaluation of other new radiotherapy techniques such as this in the 
future. 
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One consistent observation from current radiotherapy studies is that despite advances 
in radiotherapy techniques there are still a proportion of patients in whom the tumour 
exhibits primary radiation resistance. These tumours are characterised by persistence 
through radiotherapy or rapid recurrence soon after completion of treatment. These 
recurrent or persistent tumours occur within the high dose volume of PTV1 and are 
associated with a very poor prognosis. It is postulated that the reasons for primary 
radiotherapy resistance are due to a number of factors including hypoxia, tumour 
proliferation or ability to rapidly repair radiation induced DNA damage. 
 
In the future a number of different strategies will be used to try and overcome these 
issues. First, are the physical strategies. The processes of hypoxia or proliferation 
may be imaged using a number of functional imaging techniques. These include the 
use of radiopharmaceutical tracers for example 18F-misonidazole or CuATSM for 
hypoxia, or dynamic MRI techniques such as dynamic contrast enhanced (DCE) or 
diffusion weighted (DW) MRI. At the present time these techniques are experimental, 
but in the future if they show adequate sensitivity and stability these may provide 
targets for radiation dose escalation to subvolumes contained within tumours. 
Radiation doses of up to 150% of current prescriptions may be needed to overcome 
the relative radioresistance of hypoxia for example.   
 
Second, there are pharmaceutical approaches. The normal cellular response to DNA 
damage is to enter cell cycle arrest to allow repair of DNA damage. In normal cells 
this process is mediated by the intracellular protein p53 which recognises and initiates 
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repair of DNA. In many tumours p53 is mutated and the tumour cell relies on another 
pathway through Chk1 to allow cell cycle arrest and DNA repair. Therefore in some 
tumour cells with mutated p53 it may be possible, by Chk1 inhibition, to block this 
alternative DNA repair pathway and therefore render cells more sensitive to DNA 
damage. Such strategies may be tumour specific as most normal tissues have intact 
p53 and therefore will continue to repair DNA damage in normal cells in the usual 
way. There are now a number of drugs which may inhibit this DNA repair process in 
tumour cells and these will be tested in clinical trials in the next few years.  
 
In summary, I believe that we have only just started to scratch the surface of what is 
possible with modern radiation technology. The next decade will see further advances 
in technology and our understanding of cancer biology which will allow more 
accurate radiation delivery to tumours and will translate into further reductions in side 
effects and improvements in tumour control rates   
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